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Medicaid Risk-Adjustment Model with Diagnosis and Pharmacy-Based Adjusters: 
Does It Work? 
Yanen Li 
ABSTRACT 
National health expenditures will continue to grow faster than nominal gross 
domestic product (GDP) in the early 21st century (Heffler et al., 2002; Heffler et al., 
2005). Increased Medicaid costs have spurred research to find reliable cost-saving 
methodologies (Kronick et al., 1996). The Medicaid administrations of some states 
have chosen risk adjustment as a methodology for savings (Tollen et al., 1998; 
Weiner et al., 1998), since it can reduce the financial burden of health care providers 
and distribute medical resources more efficiently. This dissertation presents a risk-
adjustment model based on two types of health condition adjusters: diagnosis-based 
HCC adjusters and pharmacy-based RxRisk adjusters. HCC adjusters were developed 
from different diagnostic categories from inpatient, outpatient and long-term care 
data. RxRisk adjusters included diseases inferable from prescription drug usage. The 
underlying assumption is that using both types of health condition adjusters, rather 
than relying on either diagnosis-based adjusters or pharmacy-based adjusters alone 
can help increase predictive power and lower Medicaids risk of reimbursing inflated 
medical costs for its beneficiaries. The population in this study consisted of all 
disabled and aged Florida adults who were eligible for Floridas Medicaid program in 
state fiscal year (SFY) 2002-03 and state fiscal year 2003-04. The population was 
broken down into two subpopulations: disabled Medicaid beneficiaries aged 64 and 
under and beneficiaries aged 65 or over.  
 v
The proposed regression model includes diagnostic and pharmacy-based 
adjusters, and this dissertation compares the proposed model with models based 
solely on pharmacy- or diagnosis-based adjusters.  
The results presented in this dissertation demonstrate the proposed model 
has higher predictive power than the diagnosis-based HCC model and the pharmacy-
based RxRisk model for the overall population and the subpopulations in this study. 
Risk-adjustment models using diagnostic and prescription drug information have 
higher predictive power and decrease the possibility of inappropriate gaming of the 
Medicaid capitation payment system. 
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Chapter One 
Introduction 
  National health expenditures continue to grow faster than nominal gross 
domestic product (GDP). Some researchers (Heffler et al., 2002) have projected that 
national health expenditures will be $2,815.8 billion in 2011 and will constitute 
approximately 17 percent of GDP. This compares with 13.2 percent in 2000. Heffler 
and colleagues (2005) also predicted that national health expenditures would 
comprise 18.7 percent of the GDP in 2014.  
Health spending can be divided into two categories: the public and private 
sectors (Levit et al., 2003). Public-sector health spending includes Medicare and 
Medicaid expenditures. Medicare is a federal program that pays for hospitalization, 
physician services, short-term nursing home care, and outpatient care expenses for 
the aged. It also pays for medical care for the permanently disabled. In the past 
century, Medicare could not cover outpatient prescription drug costs. However, 
Medicare beneficiaries began receiving Medicare drug benefits under the Medicare 
Part D program on January 1, 2006. Medicaid is funded by the federal and state 
governments and provides health care and health-related services to eligible low-
income individuals and people with disabilities. Private health insurance and out-of-
pocket expenditures constitute the private sector of national health spending. The 
growth of private spending was expected to slow down sharply in 2006 when the 
Medicare drug benefit plan was introduced. However, the growth of public-sector 
health expenditures could accelerate because Medicare started covering some 
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prescription drug costs which were paid by beneficiaries prior to the introduction of 
the Medicare Part D program (Heffler et al., 2005).  
The growth of Medicaid expenditures may also accelerate for another reason; 
a slowdown in the economy may lead to more Medicaid enrollees, since Medicaid 
serves low-income individuals (Weil, 2003). Other factors associated with higher 
Medicaid costs include increased health care costs and costs associated with 
advanced medical technology. Medicare costs are less influenced by the economy 
since all people aged 65 or older are eligible for Medicare. 
The acceleration of Medicaid spending has encouraged research into cost-
containment methods. Some methods emphasize the control of prescription drug 
costs: drug formulary, a price ceiling on drugs, prescription-renewal limitations, 
dollar limits per prescription, and co-payment plans (Moore and Newman, 1993). 
Drug formularies are lists of drugs reimbursable for certain diagnoses. State Medicaid 
offices can establish pharmacy and therapeutics committees to evaluate drug 
formularies. The pharmacy and therapeutics committee approves drugs for Medicaid 
reimbursement. Moore and Newman (1993) evaluated the drug formulary 
methodology and suggested the restriction of prescription drug usage may yield a 
lower level of health benefits and fail to lower medical costs significantly. Lower drug 
usage may be associated with a surge in alternative therapy use, eventually 
increasing total health care costs. Since prescription drug costs are part of total 
medical expenditures, including physician and inpatient services, simply controlling 
prescription drug benefit alone may inadvertently result in limited and incomplete 
cost savings (Dranove, 1989; Moore and Newman, 1993).  
Another cost-containment strategy is reducing payment rates for some 
physician and outpatient services. This strategy may shift the financial burden to 
health care providers and lower medical costs inefficiently.   
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 Increased Medicaid costs have stimulated health care researchers and 
policymakers to find more feasible and reliable cost-saving methodologies. The 
Medicaid administrators of many states have chosen risk adjustment because it can 
reduce the financial burden on health care providers and distribute medical resources 
more efficiently. Risk-adjustment strategies use the health status of patients to 
predict future medical costs. Researchers review diagnoses or prescription drug 
usage to infer health status of beneficiaries and build risk-adjustment models based 
on inferred health status and other variables. Such models have been reported to 
have higher predictive power than models based solely on demographic factors such 
as age, gender, and geographic location for projecting medical expenditures (Ellis et 
al., 1996; Pope et al., 2000; Riley, 2000). Health plans tend to enroll healthier 
patients under capitation systems based on demographic factors, which provides 
them with greater profit margins, since predicted costs for healthier and sicker 
patients are equal under demographic models. Risk-adjustment models can more 
equitably reimburse health plans having a large proportion of sick enrollees and 
decrease incentives to enroll the healthiest enrollees (Ash et al., 2000; Ettner et al., 
2000; Pope et al., 2000). 
 Some risk-adjustment models may establish perverse incentives (Fishman et 
al., 2003; Gilmer et al., 2001; Pope et al., 2000). For example, models based on 
primary inpatient diagnosis encourage more hospitalization (Pope et al., 2000). 
Outpatient services  that tend to be less expensive than corresponding inpatient 
services might in some cases be inadvertently replaced with inpatient services, and 
models based on prescriptions have been shown to actually increase prescription 
drug usage (Fishman et al., 2003; Gilmer et al., 2001). 
 State Medicaid offices have been actively seeking a capitation payment 
system based on a risk-adjustment model having high predictive power and low 
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potential for gaming. This dissertation presents a model based on multiple types of 
health status predictors, which are assumed to increase predictive power and lower 
the risk of gaming by providers. 
Study Rationale 
In the past two decades, researchers have tried to establish a risk-adjustment 
model with a high predictive capacity for both Medicare and Medicaid capitation 
payment systems. Models have been built on diagnoses (Ash et al., 2000; Ellis et al., 
1996; Fishman et al., 2003; Kronick et al., 2000; McCall and Korb, 1998; Pope et 
al., 2000) and on prescription drug usage (Fishman et al., 2003; Meenan et al., 
2003; Sales et al., 2003; Sloan et al., 2003). Both models have advantages and 
disadvantages, and these are discussed in the literature review section. The purpose 
of this dissertation is to build a new predictive model for the Florida Medicaid 
capitation payment system that draws on both diagnoses and prescription drug 
usage from patient claims files. 
Review of the Literature 
Many studies have been undertaken to examine risk-adjustment 
methodologies for the Medicare capitation payment system. Although the goal of this 
dissertation is to build a new risk-adjustment model for the Medicaid capitation 
payment system, the literature on risk adjustment for Medicare capitation payment 
is reviewed since Medicare and Medicaid cover similar medical costs of their 
beneficiaries.  
Starting in the 1980s, Medicare beneficiaries could choose managed care 
plans as an alternative to the fee-for-service option. The Health Care Financing 
Administration (HCFA) compensates managed care organizations by a predetermined 
payment amount for each Medicare health maintenance organization (HMO) enrollee, 
according to capitation rates set in advance. Before risk-adjustment models, the 
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adjusted average per capita cost (AAPCC) model was launched in 1985. The 
capitation payment of the AAPCC model is calculated by the formula: Payment = 
(0.95)* (County Per Capita Costs/Average County Demographic Score)*Enrollee 
Demographic Score. Under the AAPCC model, health plans are reimbursed according 
to a predetermined amount predicted by Medicaid beneficiaries demographic 
characteristics only (age, gender, welfare status, and institutional status); the health 
status of Medicare beneficiaries is not used as a predictor in this model. Some 
researchers reported that Medicare HMOs could cherry-pick healthier beneficiaries 
from the Medicare population (Brown, 1988; Brown et al., 1993; Hill & Brown, 1990; 
Lichtenstein et al., 1991; Mello et al., 2003; Morgan et al., 1997) since sicker 
beneficiaries may have higher medical costs than predicted based on demographic 
models. Medicare HMO beneficiaries also have lower mortality rates than Medicare 
fee-for-service (FFS) beneficiaries (Brown, 1988; Brown and Langwell, 1988). The 
AAPCC model explained only 1 percent of the variance in total annual medical 
expenditures of Medicare beneficiaries (Ash et al., 1989; Ellis et al., 1996; 
Newhouse, 1986). Some researchers suggest an ideal risk-adjustment model could 
predict 20 to 25 percent of the variance in medical costs (Newhouse et al., 1989). 
Since the AAPCC model has much lower predictive power than an ideal model, it 
does not have enough capacity to predict medical costs accurately. Predicted medical 
costs can be significantly higher than actual medical costs for healthier patients and 
lower for sicker patients.  
 Several researchers discuss models based on other risk adjusters; self-
reported health status (Fowles et al., 1996; Hornbrook and Goodman, 1996), 
perceived health status (Epstein and Cumella, 1988; Gruenberg et al., 1996; 
Hornbrook and Goodman, 1996) or functional status (Epstein and Cumella, 1988; 
Hornbrook and Goodman, 1996; Lichtenstein and Thomas, 1987) has been used to 
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build risk-adjustment models. However, some researchers argue that it is time-
consuming and costly to collect self-report data (Pacala et al., 2003). 
 Compared to self-reported health and functional status, diagnoses in claims 
files have advantages as medical cost predictors: (1) they are easy to obtain from 
hospital records or physicians offices; (2) they are made by physicians, and hence 
more objective than self-reported predictors; (3) the collection costs are lower since 
diagnoses are extant in hospitalization and outpatient files. Comparisons of model 
performance have yielded varying results: some researchers report diagnosis-based 
models have higher predictive power than models based on self-reported health 
status (Fowles et al., 1997) while opposite results were reported by Pacala and 
colleagues (2003). Generally, when diagnoses are available, researchers recommend 
using diagnosis-based models (Fowles et al., 1997; Hornbrook and Goodman, 1996).  
 A new Medicare capitation payment system as well as health status risk 
adjusters were mandated under the Balanced Budget Act of 1997; and the new 
system went into effect in 2000. Since diagnosis-based models have higher 
performance, the Health Care Financing Administration (HCFA) incorporates 
diagnostic information into the Medicare capitation payment system, and has funded 
studies on different risk-adjustment methods based on diagnostic information. These 
methods include the Principal Inpatients Diagnostic Cost Group (PIPDCG) model 
based solely on inpatient data, the multi-condition Hierarchical Condition Category 
(HCC) model based on inpatient and outpatient diagnoses, and the pharmacy-based 
RxRisk model.  
The demographic AAPCC model was initially incorporated into the Medicare 
capitation payment system. Since the AAPCC model lacks predictive power (Ash et 
al., 1989; Newhouse, 1986; Pope et al., 2000) and the ability to prevent health 
plans gaming the Medicare capitation payment system (Brown et al., 1986; 1988; 
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1993; Brown and Langwell, 1987; Eggers and Prihoda, 1982; Lubitz and Prihoda, 
1984; Beebe, Lubitz, and Eggers, 1985), Congress passed the Balanced Budget Act 
of 1997 and requested the HCFA to replace the AAPCC model with a risk-adjustment 
model before January 1, 2000. The PIPDCG model was chosen to be part of the 
Medicare capitated payment system in 2000. The PIPDCG model was developed by 
researchers at Boston University, Brandeis University, Harvard University, and Health 
Economics Research, Inc. and it was selected because it could be developed in a 
short time frame. As a model based solely on inpatient data, the PIPDCG model is 
more feasible than other models because hospitalization data are easily obtained 
from health plans and health care providers, and hospitalization data are associated 
with the severity of clinical diseases and symptoms (Pope et al., 2000). Data of short 
hospital stay (less or equal to one day) are excluded from the PIPDCG model 
because Medicare beneficiaries can be inappropriately hospitalized for higher 
Medicare reimbursement by health plans.  
Demographic variables of the PIPDCG model are similar to the variables of the 
AAPCC model (Pope et al., 2000). In the AAPCC model, demographic adjusters are: 
age, gender, welfare status, and institutional status. Beneficiaries are divided into 20 
categories, 10 for men and the other 10 for women. In the PIPDCG model, the only 
change is that the age 85 or over group in the AAPCC model was removed and the 
age 85-89, age 90-94, and age 95 or over categories were added to the 
PIPDCG model. There are 24 age-gender categories in the PIPDCG model. Medicaid 
status is included in the PIPDCG model, and institutional status is removed because 
it was found to have no significant effect on annual medical expenditures in the 
PIPDCG model (Pope et al., 2000). 
The Originally disabled variable is another demographic adjuster introduced 
in the PIPDCG model. Disabled Medicare beneficiaries can be enrolled in the Medicare 
 8
program when they are younger than 65 years old under specific conditions. Their 
medical costs are significantly higher than other beneficiaries, and an originally 
disabled adjuster may predict an increase in medical costs after controlling for other 
variables (Pope et al., 2000). Working-age status is another demographic adjuster 
used in the PIPDCG model, and it refers to Medicare beneficiaries who are employed 
and offered private insurance when they receive Medicare benefits. When Medicare 
beneficiaries qualify for working-age status, 21 percent of their medical costs are 
paid by Medicare. 
 Researchers (Ash et al., 1989; Ellis and Ash, 1995; Ellis et al., 1996; Pope et 
al., 2000) developed the PIPDCG model by using the primary diagnosis in 
hospitalization data and categorizing diagnoses into certain diagnostic cost groups 
(DCGs). Since diagnoses in hospitalization data were coded according to the 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-
CM), the DCGs are built on 14,000 ICD-9-CM codes (Ash et al., 1989; Ellis and Ash, 
1995). Ellis and Ash (1996) classified 104 groups of diagnoses into 143 principal 
inpatient DXGROUPs, and these principal inpatient DXGROUPs were regrouped into 
25 PIPDCG categories. Pope and colleagues (2000) made refinements by 
categorizing the ICD-9-CM codes (more than 15,000) into 172 Principal Inpatient 
Diagnostic Groups (PIPDxGs), and created 26 PIPDCG categories. A new PIPDCG 
category added was PIPDCG 4, which is no or excluded inpatients admissions, 
ectopic pregnancy, miscarriage/terminated pregnancy, completed pregnancy with 
major complications, completed pregnancy with complications, completed pregnancy 
without complications (normal delivery). Each PIPDCG category represented a group 
of diseases that were clinically related and required similar payments. Rare diseases 
were excluded when researchers developed them from a five-percent sample of 
Medicares FFS enrollees. Ranks of PIPDCG categories were positively associated with 
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medical costs after adjustment of demographic predictors. For example, PIPDCG 29, 
which is the HIV/AIDS, bloods, lymphatic cancer/neoplasms category, is the 
reference patient group with the highest average medical expenditures ($30,456) in 
1996 (Pope et al., 2000). PIPDCG 4 was referred to as the group of people who were 
not hospitalized or who were hospitalized without significant increases in medical 
expenditures after adjusting for demographics. 
 The PIPDCG model included demographic and 16 PIPDCG variables (Pope et 
al., 2000). As a prospective risk-adjustment model, the PIPDCG model has more 
predictive power than the AAPCC model (Ellis et al., 1996; Pope et al., 2000). Ellis 
and colleagues (1996) report that the R2 value of the PIPDCG model was 5.5 
percent, and Pope and colleagues (2000) report an R2 value of 6.2 percent, 
compared with the lower value of the AAPCC model (1 percent). Consistent results 
can be found in other studies (McCall and Korb, 1998; Robinson and Karon, 2000; 
Temkin-Greener, 2001). Since Pope and colleagues (2000) re-code the PIPDXGs and 
make some refinements to the PIPDCG model, 6.2 percent may be closer to the 
predictive power of this model. Moreover, Pope and colleagues (2000) use a five-
percent sample of Medicares FFS enrollees in 1995 and 1996, consistent with the 
1991 and 1992 sample (Ellis et al., 1996) used to establish the PIPDCG model. Other 
studies (McCall and Korb, 1998; Robinson and Karon, 2000; Temkin-Greener, 2001) 
have produced similar results, while samples drawn from these studies have studied 
different groups of Medicare beneficiaries. 
 Predictive ratio is another measure used to evaluate model performance of 
risk-adjustment models.  The calculation of predictive ratio is based on the formula: 
predictive ratio = average medical costs predicted by risk-adjustment models divided 
by the average actual medical costs.  Since we evaluate risk-adjustment models by 
their capacity to predict actual medical costs, a predictive ratio close to 1 indicates 
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better model performance than a value that differs significantly from 1. Consistent 
findings (Ellis et al., 1996; Health Care Financing Administration, 1999; Pope et al., 
2000; Riley, 2000) show that the PIPDCG model has predictive ratios closer to 1 in 
different subgroups of Medicare beneficiaries than the AAPCC model. For example, 
Pope and colleagues (2000) report that the predictive ratios are 2.57, 1.88, 1.35, 
0.96, and 0.47, respectively, for five subgroups of Medicare beneficiaries according 
to their medical costs in the AAPCC model, compared with 2.09, 1.54, 1.10, 0.84, 
and 0.75 in the PIPDCG model. The PIPDCG model has a better predictive ratio in all 
subgroups except the group whose medical costs fall within a range of 60 to 80 
percent of the highest annual medical expense of Medicare beneficiaries. The PIPDCG 
model also outperforms the others for all chronic conditions and for frail elders with 
functional status difficulties. Ellis et al. (1996) and Riley (2000) found the PIPDCG 
model has a better predictive ratio in subgroups of Medicare beneficiaries who have 
impairment of 1-2, 3-4, and 5-6 ADLs. These results were later confirmed in a study 
by Pope and colleagues (2000). 
 As the first diagnosis-based model incorporated into the Medicare capitation 
payment system, the PIPDCG model has demonstrated more predictive accuracy 
than the AAPCC model. However, the R2 value is far below the ideal value (Pope et 
al., 2000). Other models have been found to be more competitive in predicting the 
variance of future medical costs. For example, the HCC model R2 value of 8.08 
percent was found to be better than the PIPDCG models R2 value of 5.53 percent 
(Ellis et al., 1996).  
 The PIPDCG model has been criticized by researchers (Miller and Luft, 1997; 
Pope et al., 2000; Health Care Financing Administration, 1999) for several 
shortcomings: First, the data source for the development of the PIPDCG model is 
inpatient data only. Both ambulatory and outpatient data can have significant effects 
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on the prediction of future medical costs but these data are not used in the PIPDCG 
model. Health plans can be more profitable by hospitalizing Medicare HMO enrollees 
who actually only need outpatient or ambulatory services because inpatient medical 
care is much more expensive than outpatient services. Second, only the primary 
diagnosis is used to evaluate patients health condition in hospitalization data, while 
other diagnoses associated with significant increases in future medical costs are not 
counted. The HCC model incorporates more information about diagnoses in the risk-
adjustment model.  
 Researchers (Ellis et al., 1996; Ash et al., 1998; Pope et al., 1998) developed 
and examined the HCC model in the late 1990s. The HCC model, as a type of risk-
adjustment model that can use information from outpatient and long-term care data, 
has more predictive power than the PIPDCG model based solely on inpatient data 
(Ellis et al., 1996).  
 Both the HCC model and the PIPDCG model have been developed from 
15,000 ICD-9-CM codes because ICD-9-CM codes are generally used in all types of 
data from claims submitted by hospitals and physicians offices. Compared with 172 
PIPDxGs in the PIPDCG model, in the HCC model there are 543 DxGROUPs clustered 
from ICD-9-CM codes. Each DxGROUP refers to a group of clinically related diseases 
and symptoms. Furthermore, 543 DxGROUPs are classified into 118 Condition 
Categories (CC) and each CC includes DxGROUPs with similar predicted medical 
costs. Advantages of CCs over PIPDCG categories are: (1) there are more CCs in the 
HCC model than PIPDCG categories in the PIPDCG model, hence the HCC model sets 
a clearer criterion for coding diagnoses from raw data. Since the PIPDCG model has 
26 PIPDCG categories only making it easier for health plans to intentionally change a 
lower PIPDCG rank to a higher PIPDCG rank linked with higher medical costs thus 
increasing profits. The PIPDCG model has obscure classification criteria for some 
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medical disorders because of its few categories. The categorization of CCs is more 
likely to be accurate than is the case for PIPDCG categories preventing a health plan 
from gaming the capitation payment system by manipulating diagnostic coding. (2) 
CCs are specifically designed for practical use on all types of data and therefore are 
more appropriate for this purpose. Since ambulatory and outpatient data are 
submitted by hospitals and physicians offices, the HCC model has the advantage of 
using all available information. (3) The HCC model counts multiple diagnoses, while 
the PIPDCG model counts only the primary diagnosis. Under the capitation payment 
system based on the PIPDCG model, health plans that have Medicare beneficiaries 
with multiple health problems are significantly underpaid because only treatment for 
the primary medical problem is reimbursed in the PIPDCG model. Pope and 
colleagues (2000) report that the predictive ratios for Medicare beneficiaries with two 
admissions and beneficiaries with three or more admissions are 0.91 and 0.69 
respectively. However, the predictive ratios for Medicare beneficiaries with zero and 
beneficiaries with one admission were 1.07 and 1.02 respectively, which over-
predicts the true value. Although patients can be hospitalized several times with the 
same diagnosis, it is more likely patients are admitted to hospital with different 
diagnoses. Hence, evidence that health plans enrolling patients with multiple hospital 
admissions are underpaid indicates that the PIPDCG model underestimates actual 
medical costs of patients with multiple diagnoses. These results are consistent with 
those found in other studies (Ellis et al., 1996; Health Care Financing Administration, 
1999). 
Demographic adjusters of the HCC model are slightly different from those of 
the PIPDCG model. Age is clustered into 15 categories: 0-5 years, 6-12 years, 13-17 
years, 18-24 years, 25-34 years, 35-44 years, 45-54 years, 55-64 years, 65-69 
years, 70-74 years, 75-79 years, 80-84 years, 85-89 years, 90-94 years, and 95 
 13
years or over (Ash et al., 2000). In the PIPDCG model, age categories are 0-34 
years, 35-44 years, 45-54 years, 55-59 years, 60-64 years, 65-69 years, 70-74 
years, 75-79 years, 80-84 years, 85-89 years, 90-94 years, and 95 years or over 
(Pope et al., 2000). The PIPDCG model divides the 55-64 years category into two 
sub-categories: the 55-59 years category and the 60-64 years category. The 
Medicaid status variable is added to the HCC model. Unlike the PIPDCG model, 
there are five eligibility categories in the HCC model: blind/disabled, other medical 
problems, poverty, pregnant women, and others.  
 As health status adjusters of the HCC model, CCs play a different role than 
the PIPDCG categories do. Patients can be assigned to multiple CCs, but only one 
PIPDCG category. CCs are divided into subgroups and a hierarchy imposed within 
each subgroup. For example, the subgroup neoplasm includes seven CCs: CC6 (high-
cost cancer), CC7 (moderate-cost cancer), CC8 (lower-cost cancers/tumors), CC9 
(carcinoma in situ), CC10 (uncertain neoplasm), CC11 (skin cancer, except 
melanoma), and CC12 (benign neoplasm). CC6 ranks the highest in this subgroup, 
and only CC6 is counted if a patient can be categorized into CC6 and another CC in 
the neoplasm subgroup. Only the CC with the highest rank is counted when a patient 
has multiple CCs of the same subgroup according to the HCC hierarchy system. 
However, CCs from different subgroups can be accumulated at the same time. For 
example, CC1 (HIV/AIDS), CC6 (high-cost cancer), and CC19 (liver disease) can be 
assigned to the same patient because these CCs are in different subgroups. Meenan 
and colleagues (2003) refine the HCC model that has 34 demographic adjusters and 
31 CC adjusters, as another version. 
The R2 value of the HCC model has a broad range − from 8.1 percent to 15.9 
percent (Ash et al., 2000; Ellis et al., 1996; Fishman et al., 2003; Kronick et al., 
2000; McCall and Korb, 1998; Sales et al., 2003). The samples in these studies are 
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different, however, the HCC model was found to have the greatest predictive power 
when it was compared to the AAPCC model, the PIPDCG model, and the pharmacy-
based RxRisk model in previous studies (Fishman et al., 2003; Sales et al., 2003). 
The investigators (Ellis et al., 1996; Kronick et al., 2000; McCall and Korb, 1998) 
conclude that the HCC model has a predictive ratio closer to 1.0 than the AAPCC 
model, the PIPDCG model, and the RxRisk model. Ellis and colleagues (1996) report 
that the predictive ratios are 1.30, 1.24, 1.14, 0.99, and 0.85 for the five subgroups 
of Medicare beneficiaries in the HCC model, while the predictive ratios are 1.92, 
1.37, 1.01, 0.78, and 0.85 in the PIPDCG model. The study is based on a national 
sample of Medicare beneficiaries, and the HCC model has better predictive ratios 
than the PIPDCG model in this study.  
 A disadvantage of the HCC model is that health plans can abuse the Medicare 
capitation payment system (Ash et al., 2000; Ellis et al., 1996). Health plans can 
replace lower-ranked CCs with higher ranked ones. Since multiple CCs can be 
counted for the same patient, health plans can inflate CC counts and receive more 
reimbursements.  
As a means of correcting some of the problems evident in diagnosis-based 
models, several pharmacy-based RxRisk models have been developed in the past 
two decades. Two of them are based on the Chronic Disease Score (Von et al., 1992) 
designed by the Center for Health Studies, Group Health Cooperative of Puget Sound 
(GHC). Prescription drugs in current medical practice are reviewed by a panel of 
physicians and health services researchers, and CDS categories are created by 
researchers. Since the original CDS model was related only to adult chronic 
conditions, a pediatric CDS model has also been developed by Fishman and Shay 
(1999). Based on the CDS and pediatric CDS model, the RxRisk model and the 
RxRisk-V model have been developed and discussed in several studies (Gilmer et al., 
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2001; Fishman et al., 2003; Meenan et al., 2003; Sales et al., 2003; Sloan, 2003).  
The major difference between the RxRisk model (Fishman et al., 2003; 
Meenan et al., 2003; Sales et al., 2003) and the RxRisk-V model (Sales et al., 2003; 
Sloan et al., 2003) is the method of categorization. The RxRisk model consists of 28 
adult RxRisk factors and 24 pediatric RxRisk factors. Sloan and colleagues (2003) 
review RxRisk categories and establish 45 RxRisk-V categories. Two RxRisk 
categories are replaced by four RxRisk-V categories: anticoagulation, antiplatelet 
agents, ischemic heart disease/angina, and congestive heart failure/hypertension. 
 Diagnosis-based models, compared with pharmacy-based models, have been 
reviewed by investigators (Gilmer et al., 2001; Fishman et al., 2003; Sales et al., 
2003; Sloan et al., 2003). Three disadvantages of diagnosis-based models have been 
identified: (1) Some health plans and HMOs do not collect diagnostic data routinely 
while pharmacy data is recorded in all claims files. (2) Reliability of diagnoses data 
can be questionable because of faulty recording, while pharmacy data are more 
reliable. (3) Health plans can become more profitable by gaming capitation payment 
systems. There is a general consensus that pharmacy-based models decrease the 
possibility of gaming because drugs used in clinical practice must be correctly 
recorded by hospitals and physicians offices. 
Diagnosis-based models, however, do have certain advantages over 
pharmacy-based models (Fishman et al., 2003). For example, the HCC model has 
more variables than the RxRisk model and the RxRisk-V model, and can identify 
more diseases than the RxRisk model and the RxRisk-V model. A shortcoming of 
RxRisk and RxRisk-V factors is that they have been developed from outpatient 
pharmacy data, and designed for chronic conditions only.  
 Age and gender are major demographic variables in the RxRisk model and the 
RxRisk-V model. On the other hand, the Medicaid status variable is not included in 
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pharmacy-based models, unlike the HCC model and the PIPDCG model. The critical 
outcome of course is the proportion of variance accounted for. The R2 value of the 
RxRisk model and the RxRisk-V model has been reported by different researchers 
(Fishman et al., 2003; Meenan et al., 2003; Sales et al., 2003; Sloan et al., 2003); 
the R2 value for the RxRisk model ranges from 7.7 percent (Fishman et al., 2003) to 
11.1 percent (Sales et al., 2003) while the R2 values for the RxRisk-V model ranges 
from 10.0 percent (Fishman et al., 2003) to 12.2 percent (Sloan et al., 2003). Sloan 
and colleagues (2003) compare the model performance of the RxRisk model with 
that of the RxRisk-V model, and report that the RxRisk-V model can explain more 
variance of medical expenses. The HCC model has outperformed pharmacy-based 
models in earlier studies (Fishman et al., 2003; Sales et al., 2003). 
Hypothesis and Research Questions 
 In the previous studies, researchers typically built a risk adjustment model 
based on one class of health condition variables. Some models used HCC adjusters 
that utilize information on diagnoses from inpatient and outpatient files. The 
diagnosis-based HCC model is the most common risk adjustment model 
implemented in the current Medicare and Medicaid capitation payment systems. 
However, there are shortfalls of diagnosis-based models in clinical practice. First, 
diagnostic variables are just one of several factors which have effects on medical 
costs. Consider that two patients with the same bacterial infection may have 
different medical costs since one is allergic to inexpensive antibiotics and requires 
more expensive medicine. Consequently, the patient with the allergy will have much 
higher medical costs than the patient who is treated with less expensive medications. 
Additionally, some patients may need costly medicine while others with the same 
disease need only generic drugs. Obviously, a risk adjustment model with only 
diagnosis-based adjusters will underpredict medical costs of patients with special 
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needs. Second, diagnoses can be easily manipulated by health plans since diagnoses 
are vague even after patients have been discharged from hospitals.  
Pharmacy-based models were developed as possible replacements of 
diagnosis-based models. However, pharmaceutical adjusters are only associated with 
prescription drug costs among total medical costs. Hence, it is not a good predictor 
for overall medical costs. However, pharmaceutical adjusters can provide additional 
information if they are incorporated into a risk adjustment model based on diagnostic 
adjusters. As mentioned in the earlier context, some patients have to be treated with 
more expensive medicine than other patients in the same disease group. Utilizing 
information on prescription drug usage can predict medical costs for these patients 
more accurately. Moreover, the addition variables in risk adjustment models may 
increase predictive power.  
The hypothesis of this dissertation is that addition of pharmacy-based risk 
adjusters in the HCC model can improve both predictive power and performance in 
practical implementation. A good risk adjustment model must be easily implemented 
and decrease the likelihood of gaming to the maximum degree. It is assumed the 
proposed model having both HCC and RxRisk adjusters will predict medical costs 
more accurately. This model can avoid some uncertainty associated with the HCC 
model since prescription drug use provides more information about patients health 
condition. The research questions this dissertation seeks to answer are how RxRisk 
adjusters should be entered into the HCC model and how to statistically and clinically 
evaluate model performance. The hypothesis that the proposed model can 
outperform the HCC model and the RxRisk model is tested and the research 
questions posed above are answered. 
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Chapter Two 
Population 
 The data for this dissertation was drawn from the administrative claims 
generated by 2.3 million Medicaid beneficiaries eligible for the Florida Medicaid 
program during State Fiscal Year (SFY) 2002-03 and 2003-04. A Florida SFY begins 
in July and ends the following June. SFY 2002-03 is the base year data, which was 
used to obtain information for demographic and health status variables. The SFY 
2003-04 data is the year 2 data and includes information about medical costs and 
eligible months.  
Ash and colleagues (2000) subdivide Medicaid enrollees into five groups: (1) 
the blind and disabled; (2) beneficiaries with other medical problems; (3) pregnant 
women and children; (4) beneficiaries with poverty-related entitlement; (5) and 
others; most Medicaid beneficiaries age 65 or over are also eligible for Medicare. For 
the purposes of the research reported here, two subpopulations were identified from 
the SFY 2002-03 Florida Medicaid data. The first subpopulation is Medicaid 
beneficiaries who are age 65 and older. The second subpopulation is disabled adult 
Medicaid beneficiaries who are older than 18 and younger than 65 years old. There 
were 242,193 enrollees in the aged adult subpopulation and 144,846 enrollees in the 
disabled adult subpopulation. The SFY 2002-03 Florida Medicaid data is referred to as 
the total Medicaid population in this dissertation. 
Methods 
The outcome variable is the Per Member Per Month (PMPM) cost for all 
services reimbursed by Medicaid for each beneficiary during SFY 2003-04. In order 
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to calculate PMPM, all claims for each Medicaid beneficiary were summed to obtain 
the annual total medical cost. This was divided by the Medicaid eligible months for 
the same beneficiary during SFY 2003-04. The PMPM cost includes medical expenses 
for hospitalization, prescription drugs, outpatient services, and other acute and long-
term care services. Base year data and year 2 data were merged to build multiple 
linear regression models. The combined data is used to establish model structure and 
measure model performance. The form of regression models is:  
Y = α + β1X1 + β2X2 + β3X3 + β4X4 +  + βnXn ,  
where Y represents the PMPM cost for each Medicaid beneficiary during SFY 2003-04 
and X1 - Xn represent the various demographic and health condition variables.  
 The HCC model and the PIPDCG model are both diagnosis-based risk-
adjustment models. The HCC model can include multiple diagnoses from different 
data resources, while the PIPDCG model uses only the primary diagnoses during 
hospitalization. Since the HCC model uses more information about diagnoses and has 
more predictive power, the risk-adjustment model presented in this dissertation uses 
the CC categories in the HCC model as the foundation for its diagnostic variables. 
 CC categories are developed from Diagnostic Groups (DxGroups), which are 
created from more than 15,000 International Classification of Diseases, 9th Revision, 
Clinical modification (ICD-9-CM) codes. There are 543 DxGroups, and each DxGroup 
includes a cluster of similar clinical diseases. The classification of DxGroups is made 
by researchers according to clinical criteria and physicians experience. CC categories 
are created to consist of DxGroups with similar medical costs. Hence, diseases in a 
CC category usually have clinical homogeneity and similar medical costs. In this 
dissertation, 70 CC categories are included in the HCC model and the proposed 
model. 
Only diagnostic codes in claims files were used to infer diagnoses for this 
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study. Medicaid beneficiaries can have multiple diagnoses, and hence can have 
multiple CCs. In the proposed risk-adjustment model, the diagnosis-based health 
condition variables consist only of HCC variables based on CC categories. Ash and 
colleagues (2000) examined the list of CC categories in order to avoid DCG creep, 
a coding practice that health plans employ to intentionally change diagnoses with 
lower predicted capitation payment to diagnoses having higher payment. Some CC 
categories are excluded and hierarchies are imposed to decrease frequency of vague 
coding and intentional coding proliferation (Ash et al., 2000). Every HCC variable in 
the proposed model corresponds to a CC category, which is clearly distinguished 
from other CC categories. The list of HCC variables can be seen in Table 1. 
Hierarchies contain only the medical condition associated with the highest medical 
costs in risk-adjustment models when patients have several clinically related medical 
problems. For example, CC7 is moderatecost cancer and has a higher rank than 
CC8 (lowercost cancer) in the HCC hierarchy system. Hence, only moderatecost 
cancer is used to predict medical expense if a patient has both moderatecost cancer 
and lowercost cancer. When a patient has several medical problems in the same 
hierarchy, only the highest-ranked disease is used for the prediction. For example, 
only CC7 will be retained in risk-adjustment models when a patient has CC7, CC8, 
and CC9 (carcinoma in situ). The HCC hierarchy system can be seen in Table 2.  
After imposing hierarchies in risk-adjustment models, the risk-adjustment 
model assumes the possibility of variable inflation and inappropriate coding practice 
can be well-controlled. When a patient has multiple medical problems corresponding 
to several CCs in the same hierarchy, only the highest-ranked CC is used in risk-
adjustment models. CCs with smaller numbers are higher-ranked CCs. For example, 
the order in the neoplasm1 hierarchy is: CC7 > CC8 > CC9 > CC10.  
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Table 1: The List of HCC Variables 
 HCC Number          Disease Categories 
 HCC1                     HIV/AIDS                                                                  
 HCC2                     Septicemia/Shock                                                          
 HCC5                     Opportunistic Infections                                                  
 HCC7                     Metastatic Cancer and Acute Leukemia                                      
 HCC8                     Lung, Upper Digestive Tract, and Other Severe Cancers                     
 HCC9                     Lymphatic, Head and Neck, Brain, and Other Major Cancers                 
 HCC10                   Breast, Prostate, Colorectal and Other Cancers and Tumors                 
 HCC15                   Diabetes with Renal or Peripheral Circulatory Manifestation               
 HCC16                   Diabetes with Neurologic or Other Specified Manifestation                 
 HCC17                   Diabetes with Acute Complications                                         
 HCC18                   Diabetes with Ophthalmologic or Unspecified Manifestation                 
 HCC19                   Diabetes without Complication                                             
 HCC21                   Protein-Calorie Malnutrition                                              
 HCC25                   End-Stage Liver Disease                                                   
 HCC26                   Cirrhosis of Liver                                                        
 HCC27                   Chronic Hepatitis                                                         
 HCC31                   Intestinal Obstruction/Perforation                                        
 HCC32                   Pancreatic Disease                                                        
 HCC33                   Inflammatory Bowel Disease                                                
 HCC37                   Bone/Joint/Muscle Infections/Necrosis                                     
 HCC38                   Rheumatoid Arthritis and Inflammatory Connective Tissue Disease 
 HCC44                   Severe Hematological Disorders                                            
 HCC45                   Disorders of Immunity                                                     
 HCC51                   Drug/Alcohol Psychosis                                                    
 HCC52                   Drug/Alcohol Dependence                                                   
 HCC54                   Schizophrenia                                                             
 HCC55                   Major Depressive, Bipolar, and Paranoid Disorders                         
 HCC67                   Quadriplegia, Other Extensive Paralysis                                   
 HCC68                   Paraplegia                                                                
 HCC69                   Spinal Cord Disorders/Injuries                                            
 HCC70                   Muscular Dystrophy                                                        
 HCC71                   Polyneuropathy                                                            
 HCC72                   Multiple Sclerosis                                                        
 HCC73                   Parkinsons and Huntingtons Diseases                                       
 HCC74                   Seizure Disorders and Convulsions                                         
 HCC75                   Coma, Brain Compression/Anoxic Damage                                     
 HCC77                   Respirator Dependence/Tracheotomy Status                                 
 HCC78                   Respiratory Arrest                                                        
 HCC79                   Cardio-Respiratory Failure and Shock                                      
 HCC80                   Congestive Heart Failure                                                  
 HCC81                   Acute Myocardial Infarction                                               
 HCC82                   Unstable Angina and Other Acute Ischemic Heart Disease                    
 HCC83                   Angina Pectoris/Old Myocardial Infarction                                 
 HCC92                   Specified Heart Arrhythmias                                               
 HCC95                   Cerebral Hemorrhage                                                       
 HCC96                   Ischemic or Unspecified Stroke                                            
 HCC100                 Hemiplegia/Hemiparesis                                                    
 HCC101                 Cerebral Palsy and Other Paralytic Syndromes                              
 HCC104                 Vascular Disease with Complications                                       
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 HCC105                 Vascular Disease                                                          
 HCC107                 Cystic Fibrosis                                                           
 HCC108                 Chronic Obstructive Pulmonary Disease                                     
 HCC111                 Aspiration and Specified Bacterial Pneumonias                             
 HCC112                 Pneumococcal Pneumonia, Emphysema, Lung Abscess                          
 HCC119                 Proliferative Diabetic Retinopathy and Vitreous Hemorrhage                
 HCC130                 Dialysis Status                                                           
 HCC131                 Renal Failure                                                             
 HCC132                 Nephritis                                                                 
 HCC148                 Decubitus Ulcer of Skin                                                   
 HCC149                 Chronic Ulcer of Skin, Except Decubitus                                   
 HCC150                 Extensive Third-Degree Burns                                              
 HCC154                 Severe Head Injury                                                        
 HCC155                 Major Head Injury                                                         
 HCC157                 Vertebral Fractures without Spinal Cord Injury                            
 HCC158                 Hip Fracture/Dislocation                                                  
 HCC161                 Traumatic Amputation                                                      
 HCC164                 Major Complications of Medical Care and Trauma                            
 HCC174                 Major Organ Transplant Status                                             
 HCC176                 Artificial Openings for Feeding or Elimination                            
 HCC177                 Amputation Status, Lower Limb/Amputation Complications 
Note: The list of HCC categories are copied from description of 2007 CMS-HCC 
software downloaded from the website of Center for Medicare and Medicaid Services.  
 
 Some CC categories are excluded because they have vague clinical health 
conditions or did not have significant effects on the prediction of medical costs. 
Seventy HCC variables are included in the HCC model and are used in this 
dissertations proposed model. 
The creation of HCC variables is based on the 2007 version of the CMS-HCC 
software. The CMS version of the HCC model has been incorporated into the 
Medicare capitation payment system and evaluated by researchers (Pope et al., 
2004). 
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Table 2: The HCC Hierarchy System 
Hierarchies       CC Categories 
Infection 
Neoplasm1 
Neoplasm2 
Neoplasm3 
Diabetes1 
Diabetes2 
Diabetes3 
Diabetes4 
Liver1 
Liver2 
Agina1 
Psychiatric 
Spinal1 
Spinal2 
Spinal3 
Arrest1 
Arrest2 
Heart1 
Heart2 
CVD1 
CVD2 
Vascular1 
Lung1 
Lung2 
Urinary1 
Urinary2 
Skin1 
Injury1 
Injury2 
      CC5, CC112 
      CC7, CC8, CC9, CC10 
      CC8, CC9, CC10 
      CC9, CC10 
      CC15, CC16, CC17, CC18, CC19 
      CC16, CC17, CC18, CC19 
      CC17, CC18, CC19 
      CC18, CC19 
      CC25, CC26, CC27 
      CC26, CC27 
      CC51, CC52 
      CC54, CC55 
      CC67, CC68, CC69, CC100, CC101, CC157 
      CC68, CC69, CC100, CC101, CC157 
      CC69, CC157 
      CC77, CC78, CC79 
      CC78, CC79 
      CC81, CC82, CC83 
      CC82, CC83 
      CC95, CC96 
      CC100, CC101 
      CC104, CC105, CC149 
      CC107, CC108 
      CC111, CC112 
      CC130, CC131, CC132 
      CC131, CC132 
      CC148, CC149 
      CC154, CC75, CC155 
      CC161, CC177 
 
 Pharmacy-based risk adjusters are included in the dissertation model in 
addition to the diagnosis-based adjusters. For comparison purposes, the results also 
include a model with only pharmacy-based variables, a version of the RxRisk model. 
Pharmacy-based risk adjusters are developed from the Chronic Disease Score (CDS), 
defined by Clark and colleagues (1995). Putnam and colleagues (2002) compare four 
versions of the Chronic Disease Score and report that the Clark version performs 
better. The CDS categories are developed from the National Drug Code (NDC). 
Florida Medicaid claims files have a NDC variable that can provide information about 
prescription drug usage. Since Medicaid beneficiaries can have multiple prescription 
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drug claims, they are assigned to one or several CDS categories according to the 
number of claims. Like CCs, CDS categories are not mutually exclusive. However, 
there is no hierarchy imposed on the CDS categories; only 29 CDS variables were 
available for the dissertation model and the RxRisk model in contrast to the 70 HCC 
variables.   
The CDS categories and corresponding HCC categories are listed in Table 3. 
The work for this dissertation reviewed all 29 CDS categories and finds that 12 
categories cover the same diseases with certain CC categories.     
These CDS categories are not duplicated in the dissertation model. When a 
Medicaid beneficiary uses prescription drugs in one of these CDS categories, the 
value of the corresponding HCC variable is set to 1, indicating that the patient has a 
diagnosis related to the HCC variables, even if the original value HCC is 0. For 
example, the value of HCC1 (HIV/AIDS) is set to 1 when the original value of HCC1 
is 0 but the Medicaid beneficiary is prescribed drugs in the A3 (AIDS) category.    
Six CDS categories are not used in the proposed model because they correspond to 
multiple CC categories. In this case, a patient in any of these CDS categories can be 
assigned to one of the corresponding CC categories. If we add these CDS categories 
to our models, the predicted medical costs might be inappropriately inflated through 
a coding maneuver by the health plans. The six CDS categories excluded from our 
models are: A10 (diabetes), A15 (heart disease /hypertension), A20 (malignancies), 
A7 (cardiac disease), A24 (psychotic illness), and A8 (coronary/peripheral vascular 
disease). Research for this dissertation created CDS variables for the 11 CDS 
categories without corresponding HCC variables and added them directly into the  
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Table 3: CDS Disease Categories with the Corresponding HCC Categories 
Diseases CDS Category HCC Category 
Cystic fibrosis A1 HCC107 
Diabetes A10 HCC15, 16, 17, 18, 19 
Epilepsy A11 HCC74 
Gastric acid disorder A12 None  
Glaucoma A13 None  
Gout A14 None  
Heart disease A15 HCC80, 81, 82, 83, 92 
Hyperlipidemia A16 None  
Hypertension A17 None   
Inflammatory Bowel Disease A18 HCC33 
Liver failure A19 HCC25 
End stage renal disease A2 HCC131 
Malignancies A20 HCC7, 8, 9, 10 
Pain A21 None   
Pain and inflammation A22 None  
Parkinsons disease A23 HCC73 
Psychotic illness A24 HCC54 
Renal disease A25 None   
Rheumatoid arthritis A26 HCC38 
Thyroid disorder A27 None   
Transplant  A28 HCC174 
Tuberculosis A29 None   
AIDS A3 HCC1 
Anxiety and tension A4 None   
Asthma A5 None   
Bipolar disorder A6 HCC55 
Cardiac disease A7 HCC80, 81, 82, 83, 92 
Coronary disease A8 HCC81, 82, 83 
Depression A9 HCC55 
 
dissertation model.  
The demographic parts of the HCC model, the RxRisk model, and the 
dissertation model include the same variables. There are 24 age-sex crossing 
variables that represent 24 demographic groups with different age and gender 
characteristics. These variables are:  
•  18-24-year-old female group  
• 25-34-year-old female group 
• 35-44-year-old female group 
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• 45-54-year-old female group 
• 55-64-year-old female group 
• 65-69-year-old female group 
• 70-74-year-old female group 
• 75-79-year-old female group 
• 80-84-year-old female group 
• 85-89-year-old female group 
• 90-94-year-old female group 
• 95-year-old or over female group 
• 18-24-year-old male group 
• 25-34-year-old male group 
• 35-44-year-old male group 
• 45-54-year-old male group 
• 55-64-year-old male group 
• 65-69-year-old male group 
• 70-74-year-old male group 
• 75-79-year-old male group 
• 80-84-year-old male group 
• 85-89-year-old male group 
• 90-94-year-old male group  
• 95-year-old or over male group 
Medicaid covers medically needy younger adults as well as the elderly, and 
the prevalence of certain diseases can differ significantly among various age-gender 
groups. Moreover, there can be a large gap in the average medical costs of the 
younger and older beneficiaries, even if they have the same medical problems. 
Because the dissertation model uses information about demographic characteristics 
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to predict the year 2 medical expenses of those who are healthy in the base year, 
demographic variables have an important role in risk-adjustment. 
Models with only demographic variables have low predictive power (Ash et al., 
1989; Ellis et al., 1996; Newhouse, 1986), which was the primary motivation for 
including the health condition variables mentioned above. 
 Multiple linear regression models were built for analyses in this dissertation. 
The form of the regression models is:  
Y = α + β1X1 + β2X2 + β3X3 +  + βnXn ,  
where Y represents the total amount of medical costs in the 2003-2004 year, X1 to Xn 
represent demographic, HCC, and CDS variables from SFY 2002-03 Medicaid claims. 
In other words, baseline year claims are used to flag the presence of health 
conditions, which are used to predict year 2 claims. A regression was run on the 
Medicaid populations and the entire adult aged and disabled population using the 
version 8 of the SAS software. The HCC and RxRisk models were run for comparison 
purposes. Both models have the same form as the dissertation model. 
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Chapter Three 
Results 
 The SFY 200203 Florida Medicaid data includes 2,849,493 Florida Medicaid 
beneficiaries. Eighty-one percent (N = 2,310,464) of them were eligible for Medicaid 
for at least one month in SFY 200304. The Medicaid population for this study 
included 2,310,464 Medicaid beneficiaries during SFY 2002-03. The young 
subpopulation of disabled adults consisted of 144,846 beneficiaries. The aged 
subpopulation had 242,193 Medicaid beneficiaries in SFY 2002-03.  
 In the overall Medicaid population, 59.35 percent of beneficiaries (N = 
1,371,223) were female enrollees. Eighty-nine percent of beneficiaries (N = 
2,007,004) were younger than 65 years old. 
In the aged subpopulation, 71.44 percent of beneficiaries (N = 173,028) are 
female enrollees. The 70-74-year-old female category has the largest proportion 
(15.36 percent), and the 75-79-year-old female is the second-largest group (14.65 
percent) among all demographic categories. Eighty-seven percent of the 
beneficiaries were eligible for Medicaid for 12 months in SFY 200304. Their PMPM 
total Medicaid claims was $933.01 in SFY 200304. 
In the young subpopulation of disabled adults, 57.90 percent of beneficiaries 
(N = 83,861) are female enrollees. The 55-64-year-old female category has the 
largest proportion (15.84 percent), and the 45-54-year-old female is the second-
largest group (14.91 percent) among all demographic categories. Ninety-one percent 
of the beneficiaries were eligible for Medicaid for 12 months in SFY 200304. Their 
PMPM total Medicaid claims was $1,120.09 in SFY 200304. 
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Model Performance 
 To validate the predictive power of the proposed models, the R2 value of the 
models is compared. Since the coefficient of each independent variable in the risk-
adjustment model represents the average increase in the PMPM Medicaid claims, the 
coefficients associated with each variable are also compared. Table 4 lists the 
summary statistics for the proposed model, the HCC model, and the RxRisk model 
for the Medicaid population.  
The proposed model was found to have the highest R2 value among the three 
models. The adjusted R2 value of the proposed model, which compensates for adding 
independent variables, is 0.28. This compares with 0.24 for the HCC model and 0.21 
for the RxRisk model. The proposed model also had the lowest Root Mean Square 
Error (RMSE = 944.42), which indicates variance about the predicted PMPM total 
Medicaid claims; models with a lower RMSE make better forecasts. The HCC model 
was found to have a higher R2 value and lower RMSE than the RxRisk model, 
indicating that diagnosis-based risk-adjustors are better predictors of medical costs 
than prescription-based risk-adjusters. 
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Table 4: Statistics for the Proposed Model, the HCC Model, and the RxRisk Model for 
the Medicaid population 
                                                Proposed              HCC                  RxRisk  
                                                Model                   Model                Model    
Statistics 
Number of Enrollees                   2,310,464             2,310,464          2,310,464 
Number of Predictors                 111                       99                     58 
R2                                             0.28                     0.24                  0.21 
Validated R2                                              0.28                      0.24                  0.21 
Root Mean Square Error             944.42                  970.67               991.63 
 
Variables PM          PM      PM   
Intercept 
                             
Female 
 
18-24 Years  
2534 Years  
35-44 Years  
4554 Years  
55-64 Years  
6569 Years  
70-74 Years  
7579 Years  
80-84 Years  
8589 Years  
90-94 Years  
95 Years or Over  
 
Male 
 
18-24 Years  
2534 Years  
35-44 Years  
4554 Years  
55-64 Years  
6569 Years  
70-74 Years  
7579 Years  
80-84 Years  
8589 Years  
90-94 Years  
95 Years or over 
 
HCC variables 
Infection 
HCC1                      
HCC2                      
HCC5   
1421.96
-1162.43
-1166.16
-1163.63
-1098.21 
-1057.35
-1203.56
-1127.53 
-947.78
-637.78
-270.28 
56.62
392.37 
-1179.93 
-1080.06 
-1056.33
-955.48
-883.14
-1121.33  
-1062.68
-917.62
-686.92
-359.07 
161.19 
     -
904.17 
566.58
846.56 
1680.57
-1402.50
-1387.31 
-1316.02 
-1150.19 
-1118.08
-1292.31 
-1198.10
-993.70
-635.09 
-221.92 
127.50
447.66 
-1397.55
-1244.44 
-1147.85 
-1034.14
-1004.20
-1253.70
-1181.41
-1007.34
-729.68 
-339.75
-124.73 
    -
1074.94
601.91
845.09
 
 
 
 
1309.51
-1031.62
-1036.46
-1019.74
-934.94
-889.56
-1136.32
-1083.46
-914.85
-626.84
-277.77
34.29
371.91
-982.36 
-886.34 
-874.32 
-750.79 
-650.95 
-1029.84
-999.03 
-866.76
-657.33
-364.58
-163.78
    -
    -
    -
    -
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Neoplasm   
HCC7                      
HCC8                      
HCC9                      
HCC10 
 
Endocrinal Disorders 
HCC15                    
HCC16                    
HCC17                    
HCC18                    
HCC19                    
HCC21     
 
Gastrointestinal 
Disorders 
HCC25                           
HCC26                    
HCC27                    
HCC31                    
HCC32                    
HCC33                    
 
Connective Tissue 
Disease 
HCC37                    
HCC38 
 
Hematological 
Disorders                      
HCC44                           
HCC45                    
 
Psychiatric Disorders 
HCC51                    
HCC52                    
HCC54                           
HCC55  
 
Spinal Cord Disorders 
HCC67                    
HCC68                           
HCC69   
 
Neurological 
Disorders 
HCC70                    
HCC71                           
HCC72                    
HCC73                    
HCC74                    
1190.18
462.58
218.04 
57.77  
709.10
306.12 
247.93
214.37
103.87
656.54 
534.77 
228.48 
143.71
381.66 
247.78
67.40
195.30
-6.19 
1151.22 
396.44 
0.57
39.63
440.64
166.79
2416.65
961.39 
476.58
1333.61
127.42
475.80
494.69 
588.76 
1271.69  
543.77
284.68  
82.53 
804.79
400.57
289.61
278.80
139.51
653.71
642.19
330.40
247.95
454.35
273.13
103.81
213.85 
83.54
1162.97 
447.59
85.51
126.55
725.80
364.30
2488.53
1027.30
506.94
1301.52
289.57 
672.08
813.15 
815.30
 
    -
    -
    -
    -
 
    -
    -
    -
    -
    -
    -
 
    -
    -
    -
    -
    -
    -
 
    -
    -
 
    -
    -
 
    -
    -
    -
    -
 
    -
    -
    -
 
    -
    -
    -
    -
    -
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HCC75                    
 
Respiratory Disorders 
HCC77                           
HCC78                    
 
Cardiac Diseases 
HCC79                           
HCC80                    
HCC81                    
HCC82                    
HCC83                    
HCC92     
 
Cerebral and 
Vascular Diseases  
HCC95                    
HCC96                    
HCC100                  
HCC101                  
HCC104                  
HCC105       
 
Pulmonary Diseases     
HCC107                         
HCC108                         
HCC111                  
HCC112                  
 
Eye Disorders 
HCC119                  
 
Renal Disorders 
HCC130                  
HCC131                         
HCC132                  
 
Skin Disorders              
HCC148                  
HCC149                         
HCC150                  
 
Injury 
HCC154                  
HCC155                         
HCC157                  
HCC158                         
HCC161                  
HCC164                  
 
Others 
HCC174                         
1348.61 
3896.12  
597.94
410.70 
369.33
117.29 
-20.23
-154.07
131.78
194.98 
457.79
500.44
1707.94
420.80  
343.28 
19.53
-14.13
952.72 
196.08
-37.00
692.33 
487.36
183.03 
610.57
424.29 
207.37 
864.19
140.17 
124.15 
357.44 
90.82 
387.74 
256.27 
1334.25
3922.82 
665.95
451.56
414.59  
55.77
-15.02
-127.56 
129.02
191.24
537.97
524.37
1777.23
455.21
395.69
1574.13
132.68
911.62
209.27
-22.28
1127.53
536.02 
236.06
721.78
510.83
234.00
926.78
192.38
170.77
434.85
181.45
436.66
918.76
    -
 
    -
    -
 
    -
    -
    -
    -
    -
    -
 
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
 
    -
 
    -
    -
    -
 
    -
    -
    -
 
    -
    -
    -
    -
    -
    -
 
    -
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HCC176                 
HCC177                  
 
CDS Variables    
 
A1 
A2 
A3 
A4 
A5 
A6 
A7 
A8 
A9 
A10                               
A11 
A12 
A13 
A14 
A15 
A16 
A17 
A18 
A19 
A20 
A21 
A22 
A23 
A24 
A25 
A26 
A27 
A28 
A29 
1745.14 
646.77 
 
    - 
    -
    -
163.00  
96.43
    -
    -
    -
    - 
    -  
    -
157.33
32.01 
23.47 
    -
-117.34 
54.20
    -
    -
    -
-32.82 
-150.23  
    -
    -
592.96 
    -
264.13 
    -
433.97
1827.30
699.96
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
 
18.14  
1086.18  
989.09  
224.32  
143.73  
-58.46  
284.29  
84.03 
114.01  
190.25  
740.76  
219.19  
14.63  
-29.57  
-72.46  
-201.69  
41.91  
79.34  
745.49  
428.62 
9.23  
-181.94  
454.67  
452.24  
798.12  
11.51  
231.57  
211.83
725.61
Notes: PM is Parameter. - indicates a variable that is not relevant for a particular 
model. Male patients age 95 or over are used as baseline in our models. The units of 
all medical costs are dollars. 
 
  
The age 95 years or over male group was used as the baseline age-gender 
group in all three models. Future medical costs peak at age 45 to 64 years, and then 
decrease between age 65 and 69 years. After age 65 to 69 years, future medical 
costs increase again and have a positive relationship to age. 
 The HCC variables were divided into 18 groups and compared parameters 
within each group in both the proposed model and the HCC model. Three categories 
fell within the infection group: HCC1 (HIV/AIDS), HCC2 (septicemia/shock), and 
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HCC5 (opportunistic infections). In the proposed model, Acquired Immune Deficiency 
Syndrome (AIDS) was associated with the highest increase in future medical costs 
among the three diseases, which was $904.17 in the proposed model and $1,074.94 
in the HCC model. 
The neoplasm group includes HCC7 (metastatic cancer and acute leukemia), 
HCC8 (lung, upper digestive tract, and other severe cancers), HCC9 (lymphatic, 
heart and neck, brain, and other major cancers), and HCC10 (breast, prostate, 
colorectal and other cancers and tumors). Their ranks were positively associated with 
future medical costs. For example, metastatic cancer and acute leukemia increase 
PMPM medical costs by $1,190.18 in the proposed model after other factors are 
controlled, and by $1,271.69 in the HCC model. Breast, prostate, and colorectal 
cancers are associated with a lower increase in PMPM medical costs than lung, upper 
digestive tract, and brain cancers. 
 The endocrinal disorders group includes HCC15 (diabetes with renal or 
peripheral circulatory manifestation), HCC16 (diabetes with neurological or other 
specified manifestation), HCC17 (diabetes with acute complications), HCC18 
(diabetes with ophthalmologic or unspecified manifestation), HCC19 (diabetes 
without complication) and HCC21 (protein-calorie malnutrition). Among all diabetes 
categories, diabetes with renal or peripheral circulatory manifestation was associated 
with the highest increase in the PMPM medical cost, which is $709.10 in the 
proposed model and $804.79 in the HCC model. Protein-calorie malnutrition is also 
associated with relatively high PMPM medical costs in the endocrinal disorders 
group. 
 The gastrointestinal disorders group consisted of six HCC variables: HCC25 
(end-stage liver disease), HCC26 (cirrhosis of the liver), HCC27 (chronic hepatitis), 
HCC31 (intestinal obstruction/perforation), HCC32 (pancreatic disease), and HCC33 
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(inflammatory bowel disease). End-stage liver disease was associated with the 
highest increase in the PMPM medical cost among all gastrointestinal disorders, 
which is $534.77 in the proposed model and $642.19 in the HCC model.  
 The connective tissue disease group includes HCC37 (bone/joint/muscle 
infections/necrosis) and HCC38 (rheumatoid arthritis and inflammatory connective 
tissue disease). They were associated with a moderate increase in the PMPM medical 
cost.  
 Two HCC variables fall into the hematological disorders group: HCC44 
(severe hematological disorders) and HCC45 (immune disorders). Severe 
hematological disorders are significantly associated with a high increase in the PMPM 
medical cost, which is $1,152.22 in the proposed model and $1,162.98 in the HCC 
model.  
 The psychiatric disorders group includes four categories: HCC51 
(drug/alcohol psychosis), HCC52 (drug/alcohol dependence), HCC54 (schizophrenia), 
and HCC55 (major depressive, bipolar, and paranoid disorders). Schizophrenia is 
associated with the highest increase in the PMPM medical cost in this group, which is 
$440.64 in the proposed model and $725.80 in the HCC model. 
 The spinal cord disorders group consists of HCC67 (quadriplegia, other 
extensive paralysis), HCC68 (paraplegia), and HCC69 (spinal cord 
disorders/injuries). These are associated with a high increase in the PMPM medical 
cost, especially quadriplegia and paraplegia. Quadriplegia increases the PMPM 
medical cost by $2,416.65 in the proposed model and $2,488.53 in the HCC model. 
 The neurological disorders group includes HCC70 (muscular dystrophy), 
HCC71 (polyneuropathy), HCC72 (multiple sclerosis), HCC73 (Parkinsons and 
Huntingtons Disease), HCC74 (seizure disorders and convulsions) and HCC75 
(coma, brain compression/anoxic damage). Muscular dystrophy and coma are both 
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associated with more than a $1,300 increase in the PMPM medical cost. 
 The respiratory disorders group consists of HCC77 (respiratory 
dependence/tracheotomy status) and HCC78 (respiratory arrest). Respiratory 
dependence or tracheotomy status is associated with the highest increase in the 
PMPM medical cost among all diagnoses, $3,896.12 in the proposed model, and 
$3,922 in the HCC model.  
 The cardiac diseases group includes six categories: HCC79 (cardio-
respiratory failure and shock), HCC80 (congestive heart failure), HCC81 (acute 
myocardial infarction), HCC82 (unstable angina and other acute ischemic heart 
disease), HCC83 (angina pectoris/old myocardial infarction), and HCC92 (specified 
heart arrhythmias). Cardio-respiratory failure and shock is significantly associated 
with the highest PMPM medical cost, $410.70 in the proposed model, and $451.56 in 
the HCC model.  
 The cerebral and vascular diseases group includes HCC95 (cerebral 
hemorrhage), HCC96 (ischemic or unspecified stroke), HCC100 
(hemiplegia/hemiparesis), HCC101 (cerebral palsy and other paralytic syndromes), 
HCC104 (vascular disease with complications), and HCC105 (vascular disease). 
Cerebral palsy and other paralytic syndromes are associated with the highest 
increase in the PMPM medical cost, $1,707.94 in the proposed model, and $1,777.23 
in the HCC model.  
 The pulmonary diseases group consists of four categories: HCC107 (cystic 
fibrosis), HCC108 (chronic obstructive pulmonary disease), HCC111 (aspiration and 
specified bacterial pneumonias), HCC112 (pneumococcal pneumonia, empyema, and 
lung abscess). Parameters of cystic fibrosis are very different for the proposed model 
and the HCC model − $19.53 and $1,574.13, respectively. 
 There is only one category in the eye disorders group: HCC119 (proliferative 
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diabetic retinopathy and vitreous hemorrhage). It is associated with a negative 
increase in the PMPM medical cost.  
 The renal disorders group includes HCC130 (dialysis status), HCC131 (renal 
failure), and HCC132 (nephritis). Dialysis is associated with the highest increase in 
the PMPM medical cost in this group, which is $692.33 in the proposed model and 
$1,127.53 in the HCC model.  
 The skin disorders group consists of HCC148 (decubitus ulcer of the skin), 
HCC149 (chronic ulcer of the skin, except decubitus) and HCC150 (extensive third-
degree burns). Decubitus skin ulcer is associated with the highest increase in the 
PMPM medical cost in this group, which is $610.57 in the proposed model and 
$721.78 in the HCC model.  
 The injury group includes HCC154 (severe head injury), HCC155 (major 
head injury), HCC157 (vertebral fractures w/o spinal cord injury), HCC158 (hip 
fracture/dislocation), HCC161 (traumatic amputation), and HCC164 (major 
complications of medical care and trauma). Severe head injury is associated with a 
$864.19 increase in the proposed model and a $926.78 increase in the HCC model, 
which are higher than those of other disorders in the injury group. 
 Several HCC categories are assigned to the others group: HCC174 (major 
organ transplant status), HCC176 (artificial openings for feeding or elimination), and 
HCC177 (amputation status, lower limb/amputation complications). Artificial 
openings for feeding or elimination and amputation status are significantly associated 
with relatively high increase in the PMPM medical cost. Artificial openings for feeding 
or elimination increase PMPM medical cost by $1,745.14 in the proposed model and 
$1,827.30 in the HCC model. 
 Twenty-nine CDS variables are added into the RxRisk model and 12 of them 
are also independent variables in the proposed model in this dissertation. They are: 
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A12 (gastric acid disorder), A13 (glaucoma), A14 (gout), A16 (hyperlipidemia), A21 
(pain), A22 (pain and inflammation), A25 (renal disease), A27 (thyroid disorder), 
A29 (tuberculosis), A4 (anxiety and tension), A5 (asthma), and A17 (hypertension). 
In the RxRisk model, these variables are significantly associated with a high increase 
in the PMPM medical cost: end-stage renal disease ($1,086.18), epilepsy ($740.76), 
liver failure ($745.49), renal disease ($798.12), and tuberculosis ($725.61). In the 
proposed model, renal disease and tuberculosis are also associated with high 
increases in PMPM medical costs, $592.96 and $433.97, respectively.  
The aged subpopulation included 242,192 Medicaid enrollees aged 65 and 
above. The proposed model has the best predictive performance since its R2 value 
(R2 = 0.32) and RMSE (RMSE = 1,174.92) is the highest among all models for the 
aged population. The pharmacy-based RxRisk model has slightly lower R2 value (R2 = 
0.30) and higher RMSE (RMSE = 1,187.07) than the proposed model. The HCC 
model has relatively poorer predictive performance with lower R2 value (R2 = 0.17) 
and higher RMSE (RMSE = 1,299.12) 
 In all three models for the aged subpopulation, age has a strong and linear 
effect on PMPM total Medicaid claims for both male and female groups. The PMPM 
medical costs increase significantly with a five-year increment of age. Among all age-
gender groups with beneficiaries aged 80 or above only, female beneficiaries have 
higher average PMPM medical costs than male beneficiaries. In the proposed model, 
the older male beneficiaries aged under 80 have higher PMPM medical costs than 
their female counterparts. The results of statistics for the aged subpopulation are 
shown in Table 5.  
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Table 5: Compared Statistics for the Proposed Model, the HCC Model, and the RxRisk 
Model for the Aged and the Young Disabled Adults 
Proposed Model HCC Model  RxRisk Model  
Aged Disabled Aged Disabled Aged Disabled
Statistics 
 
Number of Enrollees       
Number of Predictors     
R2                                
Validated R2  
RMSE 
242,192
93
0.32
0.32
1,174.92
144,845
91
0.25
0.25
1,627.39
242,192
81
0.17
0.17
1,299.12
 
 
144,845 
79 
0.23 
0.23 
1,648.85 
 
 
242,192 
42 
0.30 
0.30 
1,187.07 
144,845
38
0.16
0.16
1,725.33
Variables PM PM PM PM PM PM 
Intercept 
 
Female 
 
1824 Years 
2534 Years  
3544 Years  
4554 Years  
5564 Years  
6569 Years  
70-74 Years  
7579 Years  
80-84 Years  
8589 Years  
90-94 Years  
95 Years or over  
 
Male 
 
1824 Years 
2534 Years  
3544 Years  
4554 Years  
5564 Years  
6569 Years  
70-74 Years  
7579 Years  
80-84 Years  
8589 Years  
90-94 Years  
95 Years or over  
 
HCC variables 
Infection 
HCC1                            
HCC2                      
HCC5   
279.11
-
-
-
-
-
-120.97
 -47.56
 106.20
 371.59
 703.33
1018.77
1369.69
-
-
-
-
-
-
  37.84
 146.72
 323.17
 587.15
 773.01
1006.31
638.05
351.37
-253.75
524.12
-28.84
93.29
-55.73
-86.97
-78.26
-
-
-
-
-
-
-
-
237.26
84.45
0.41
31.41
-
-
-
-
-
-
-
950.89
530.62
896.15
488.57
-
-
-
-
-
-62.43
3.49
185.48
516.27
925.70
1282.72
1617.23
-
-
-
-
-
-
26.37
166.63
410.79
763.69
986.72
1140.63
1132.92
607.81
-294.49
563.48 
 
 
 
-51.84 
  94.83 
 -24.19 
 -40.88 
 -48.77 
- 
- 
- 
- 
- 
- 
- 
 
 
 
- 
256.26 
108.84 
10.91 
22.16 
- 
- 
- 
- 
- 
- 
- 
 
 
 
1039.33 
 573.93 
 959.37 
297.02 
 
 
 
- 
- 
- 
- 
- 
-122.97 
  -67.29 
   79.02 
  337.02 
  657.66 
  966.27 
 1316.01 
 
 
 
- 
- 
- 
- 
- 
- 
  16.77 
 120.29 
 287.48 
 533.99 
 721.91 
 949.89 
 
 
 
- 
    - 
    - 
705.22
-52.54
  -1.22
-211.08
-255.85
-262.44
-
-
-
-
-
-
-
-
214.23
  18.11
 -81.90
 -60.23
-
-
-
-
-
-
-
-
    -
    -
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Neoplasm   
HCC7                      
HCC8                      
HCC9                      
HCC10 
 
Endocrinal Disorders 
HCC15                    
HCC16                     
HCC17                    
HCC18                    
HCC19                    
HCC21     
 
Gastrointestinal 
Disorders 
HCC25                          
HCC26                    
HCC27                    
HCC31                    
HCC32                    
HCC33                    
 
Connective Tissue 
Disease 
HCC37                    
HCC38 
 
Hematological 
Disorders                     
HCC44                          
HCC45                    
 
Psychiatric Disorders 
HCC51                    
HCC52                    
HCC54                          
HCC55  
 
Spinal Cord Disorders 
HCC67                    
HCC68                          
HCC69   
 
Neurological 
Disorders 
HCC70                    
HCC71                          
HCC72                    
HCC73                    
HCC74                    
 329.59
-129.70
-131.86
-55.24
902.32
279.37
133.08
289.71
107.71
 769.06
   4.16
 196.95
-167.63
388.66
97.81
106.28
94.18
-49.75
211.31
 247.85
419.61
 -42.91
 954.61
 396.07
992.65
599.40
 208.78
   47.99
 -235.38
1482.59
624.72
584.43
998.78
495.47
69.38
32.44
462.09
340.70
378.67
201.77
137.68
783.46
805.47
4.62
194.06
464.33
149.00
-92.40
168.74
53.30
1278.71
496.35
-11.95
121.46
440.43
-81.48
2540.17
895.19
381.20
1710.88
137.77
320.41
413.82
647.71
508.65
142.42
-4.85
-57.23
1110.82
369.90
160.75
410.25
128.65
827.42
-242.31
271.74
-41.52
543.89
49.83
45.11
216.08
14.59
277.28
332.46
599.24
70.93
953.02
630.69
940.41
595.42
182.82
67.68
-129.38
1757.72
851.10
1059.17
 
 
1153.19 
578.79 
128.33 
66.05 
 
 
575.41 
442.04 
419.29 
252.35 
189.46 
789.10 
 
 
 
485.16 
 152.08 
 281.49 
556.99 
220.29 
-122.63 
 
 
 
157.26 
61.24 
 
 
 
1274.97 
 561.70 
 
 
   8.02 
 183.47 
 676.85 
 191.00 
 
 
2619.79 
936.97 
422.97 
 
 
 
1663.91 
313.48 
461.24 
720.18 
1070.44
 
 
    - 
    - 
    - 
    - 
 
 
    - 
    - 
    - 
    - 
    - 
    - 
 
 
 
    - 
    - 
    - 
    - 
    - 
    - 
 
 
 
    - 
    - 
 
 
 
    - 
    - 
 
 
    - 
    - 
    - 
    - 
 
 
    - 
    - 
    - 
 
 
 
    - 
    - 
    - 
    - 
    - 
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
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HCC75                    
 
Respiratory Disorders 
HCC77                          
HCC78                    
 
Cardiac Diseases 
HCC79                          
HCC80                    
HCC81                     
HCC82                    
HCC83                    
HCC92     
 
Cerebral and 
Vascular Diseases  
HCC95                    
HCC96                    
HCC100                  
HCC101                  
HCC104                   
HCC105       
 
Pulmonary Diseases    
HCC107                        
HCC108                        
HCC111                  
HCC112                  
 
Eye Disorders 
HCC119                  
 
Renal Disorders 
HCC130                  
HCC131                        
HCC132                  
 
Skin Disorders             
HCC148                  
HCC149                        
HCC150                  
 
Injury 
HCC154                  
HCC155                        
HCC157                  
HCC158                        
HCC161                  
HCC164                
 
Others 
HCC174                        
490.73
  937.73
71.88
157.94
 233.49
 -61.56
-112.26
-191.59
113.84
56.53
582.30
 506.01
1484.98
346.45
537.08
-276.54
-272.45
682.89
-82.59
-46.76
507.48
 359.16
  36.03
  581.37
  357.14
-
-
927.97
  198.52
334.12
 130.06
321.83
348.84
514.08
1489.20
485.02
292.71
392.63
171.21
81.88
-63.69
150.17
-35.43
285.71
632.72
2167.79
493.64
206.29
183.71
198.32
736.77
221.48
-40.67
1181.70
493.86
133.76
707.38
514.82
-845.99
1153.89
112.01
277.55
221.28
122.16
209.06
3.11
625.18
1089.04
443.41
399.26
359.68
-143.30
-136.20
-225.33
104.26
125.95
778.67
690.24
1642.43
435.06
680.87
152.02
-33.77
873.28
-38.93
-100.50
1050.71
456.80
-96.51
750.18
515.12
-
-
1238.58
346.92
560.90
247.82
474.12
837.32
442.88 
 
 
1542.30 
565.26 
 
 
290.09 
419.11 
168.72 
96.40 
 -32.76 
174.39 
 
 
 
-92.44 
267.36 
595.09 
2183.22 
517.01 
246.66 
 
 
1520.66 
315.80 
686.64 
232.49 
 
 
10.05 
 
 
1924.46 
 535.42 
 130.00 
 
 
756.87 
 539.20 
-965.15 
 
 
1282.70 
 116.40 
 314.13 
186.56 
 152.31 
246.58 
 
 
494.98 
    - 
 
 
    - 
    - 
 
 
    - 
    - 
    - 
    - 
    - 
    - 
 
 
 
    - 
    - 
    - 
    - 
    - 
    - 
 
 
    - 
    - 
    - 
    - 
 
 
    - 
 
 
    - 
    - 
    - 
 
 
    - 
    - 
    - 
 
 
    - 
    - 
    - 
    - 
    - 
    - 
 
 
    - 
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
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HCC176                  
HCC177                  
 
CDS Variables    
 
A1 
A2 
A3 
A4 
A5 
A6 
A7 
A8 
A9 
A10                              
A11 
A12 
A13 
A14 
A15 
A16 
A17 
A18 
A19 
A20 
A21 
A22 
A23 
A24 
A25 
A26 
A27 
A28 
A29 
512.00
451.30
-
-
-
-17.23
 326.27
-
-
-
-
-
-
  134.74
   -8.04
    5.41
-
-164.73
41.94
-
-
-
  137.14
-177.33
-
-
799.74
-
210.55
-
704.13
1378.58
689.39
-
-
-
299.51
128.45
-
-
-
-
-
-
116.84
228.47
18.75
-
-37.43
20.88
-
-
-
-167.80
-190.27
-
-
1179.06
-
209.75
-
448.37
 715.73
434.47
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
    -
1417.84 
749.75 
 
 
 
- 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
    - 
     
    - 
    - 
 
 
 
-293.85 
  514.55 
  631.87 
  -37.04 
  265.56 
   89.38 
  294.91 
   40.41 
  374.71 
  191.87 
  589.68 
  120.04 
  -24.09 
  -57.65 
  -59.59 
 -214.44 
   -3.41 
  102.12 
    5.24 
  254.95 
  114.67 
 -186.48 
  648.48 
  978.58 
  919.85 
  -89.21 
  185.84 
283.19 
 766.87 
    -
    -
 218.55
1283.73
1043.85
 398.03
 237.55
  24.43
268.26 
260.77
-167.51
 290.34
 791.41
 246.50
 280.22
 108.21
  -5.80
-145.51
  51.87
  46.75
1371.01
 826.56
 -22.35
-283.17
 349.09
 478.58
2260.73
  91.78
228.29
-101.03
1097.29
Notes: PM is Parameter. - indicates a variable that is not relevant for a particular 
model.  
 
 The young disabled subpopulation of Medicaid beneficiaries consisted of 
144,845 enrollees, compared with 242,192 enrollees in the aged subpopulation. 
Generally, the proposed model and the RxRisk model have poorer predictive 
performance in the young disabled subpopulation than in the aged subpopulation as 
indicated by lower R2 value and high RMSE in the former subpopulation. The 
proposed model explains 25 percent of variance in the young disabled adults PMPM 
medical costs, compared with 32 percent in the aged population. The R2 value of the 
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RxRisk model for the young disabled subpopulation is 0.16, compared with 0.30 for 
the aged subpopulation. However, the HCC model has higher R2 value (R2 = 0.23) for 
the young disabled subpopulation, compared with 0.17 for the aged subpopulation. 
The results of statistics for the young disabled subpopulation can also be found in 
Table 5.  
RMSE had a higher value in all three models for the young disabled 
subpopulation than the aged subpopulation. The proposed model had the lowest 
RMSE (RMSE = 1,627.39) for the young disabled subpopulation among all models.  
Age had a nonlinear effect on PMPM total Medicaid claims for the young 
disabled subpopulation in all three models. The 25-34-year-old male group and the 
25-34-year-old female group had the highest PMPM medical costs among male and 
female younger disabled adults respectively, and male beneficiaries had higher PMPM 
medical costs than female beneficiaries.  
The proposed model has better predictive performance than the HCC model 
and the RxRisk model. Among all infectious diseases, AIDS is associated with the 
highest increase in PMPM total Medicaid claims for both the aged and the young 
disabled subpopulation. The proposed model predicts that AIDS increases the PMPM 
medical cost by $638.05 in the aged subpopulation and by $950.89 in the young 
disabled subpopulation.  
Metastatic cancers and acute leukemia are associated with higher increase in 
the PMPM total Medicaid cost for both the aged and the young disabled 
subpopulation than other diseases in the neoplasm group. The proposed model 
predicts that Metastatic cancers and acute leukemia increase the PMPM medical cost 
by $638.05 in the aged subpopulation and by $950.89 in the disabled subpopulation.  
Diabetes with renal or peripheral circulatory manifestation increases the 
PMPM medical cost by $902.32 in the aged subpopulation, compared with $462.09 in 
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the disabled subpopulation. Protein-calorie malnutrition is associated with $769.06 of 
increase in the PMPM medical cost in the aged subpopulation and $783.46 of 
increase in the young disabled subpopulation.  
End-stage liver disease increases the PMPM medical cost by $805.47 in the 
young disabled subpopulation and $4.25 in the aged subpopulation. Severe 
hematological disorders are associated with $1,278.71 of increase in PMPM total 
Medicaid claims for the young disabled subpopulation, and $211.31 of increase in 
claims for the aged subpopulation. 
Schizophrenia increases the PMPM medical cost by $954.61 in the aged 
subpopulation and $440.43 in the young disabled subpopulation. Among neurological 
disorders, quadriplegia and paraplegia increase PMPM medical costs by $2,540.17 
and $895.19 respectively in the young disabled subpopulation, and $992.65 and 
$599.40 respectively in the aged subpopulation. Muscular dystrophy increases the 
PMPM medical cost by $1,710.88 in the young disabled subpopulation, and multiple 
sclerosis increases the PMPM medical cost by $1,482.59 in the aged subpopulation.  
Respiratory dependence is associated with high increase in PMPM total 
Medicaid claims, which is $937.73 in the aged subpopulation and $1,489.20 in the 
young disabled subpopulation. Among all cardiac diseases, congestive heart failure 
increase the PMPM medical cost by the largest margin, which is $233.49 in the aged 
subpopulation and $392.63 in the young disabled subpopulation.  
Cerebral palsy and other paralytic syndromes increase the PMPM medical cost 
by $1,484.98 in the aged subpopulation and $2,167.79 in the young disabled 
subpopulation. Dialysis increases the PMPM medical cost by $1,181.70 in the young 
disabled subpopulation, and a major head injury increases the PMPM medical cost 
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Table 6: Predictive Ratios in the HCC model and Proposed Model for the Aged 
Subpopulation 
Diseases Proposed Model 
PR 
HCC Model 
PR 
Acute Myocardial Infarction 
Aspiration and Specified Bacterial Pneumonias 
Cardio  Respiratory Failure and Shock 
Chronic Obstructive Pulmonary Disease 
Congestive Heart Failure 
Diabetes with Renal or Peripheral Circulatory 
Manifestation 
Dialysis Status 
End-Stage Liver Disease 
Hip Fracture/Dislocation 
Inflammatory Bowel Disease 
Ischemic or Unspecified Stroke 
Major Depressive, Bipolar, and Paranoid Disorders 
Metastatic Cancer and Acute Leukemia 
Parkinsons and Huntingtons Disease 
Renal Failure  
Schizophrenia 
1.02 
0.97 
0.93 
0.99 
0.97 
 
0.99 
1.00 
0.78 
1.00 
0.99 
0.96 
0.98 
0.78 
0.97 
0.99 
0.90 
0.91 
0.95 
0.84 
0.99 
0.93 
 
0.94 
0.99 
0.74 
1.00 
0.99 
0.96 
0.98 
0.78 
0.95 
0.97 
0.90 
Note: PR means predictive ratio. 
by $927.97 in the aged subpopulation.  
Model performance can also be evaluated by the predictive ratio. The 
predictive ratio is calculated by dividing predicted medical cost by actual medical cost 
in the year 2 data within different subgroups. The ideal value of predictive ratio is 1, 
which means the mean of predicted medical cost is equal to the mean of actual 
medical cost. Risk-adjustment models with predictive ratios closer to 1 are regarded 
as the models with higher predictive power. In Table 6, predictive ratios in the HCC 
model and the proposed model for the aged subpopulation are listed. The results 
show that the proposed model has better predictive ratios than the HCC model in all 
disease groups except chronic obstructive pulmonary disease, hip fracture, 
inflammatory bowel Disease, ischemic or unspecified stroke, major depression, 
metastatic cancers and schizophrenia.  
The aged subpopulation and the young disabled subpopulation account for 
different proportion among all Florida Medicaid beneficiaries. In SFY 2002-03, 10.5 
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percent of Medicaid enrollees were aged 65 or above and 6.27 percent of Medicaid 
enrollees were disabled adults younger than 65. The distribution of SFY 2002-03 
PMPM medical costs among two subpopulations of Medicaid enrollees is listed in 
Table 7. Except for the 90th percentile, the young disabled subpopulation has higher 
PMPM medical costs in all percentiles listed in Table 7. Figure 2 draws the picture of 
distribution of SFY 2002-03 PMPM medical costs in percentiles among two 
subpopulations. The blue triangle sign indicates the number of the younger disabled 
beneficiaries PMPM costs in each percentile strata and the red dot sign indicates the 
number of the aged beneficiaries PMPM costs in each percentile strata. The younger 
disabled beneficiaries, whose PMPM costs fall within top 5 percentiles, need much 
more reimbursements than their counterparts in the aged subpopulation.   
The average PMPM costs in various disease groups are also different for the 
aged subpopulation and the young disabled subpopulation, as shown in Figure 1. 
Among the patients with psychotic diseases, younger disabled Medicaid enrollees 
have higher PMPM costs than older enrollees. The younger patients with renal or 
pulmonary diseases including renal failure and pneumonia also need much more 
reimbursement for their health care services than their older counterparts. However, 
the younger patients with chronic heart failure have similar medical costs with their 
older counterparts. Acute myocardial infarction is associated with higher PMPM 
medical cost in the young disabled subpopulation than in the aged subpopulation. 
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Table 7: Distribution of SFY 2002-03 PMPM Medical Costs among Two Subpopulations 
of Medicaid Enrollees 
Percentile Aged Disabled 
Maximum  
99 
95 
90 
75 
50 
25 
10 
5 
1 
34838.30
  5218.20
  4322.18
  3618.42
   921.56
   311.88
    90.91
     0.00
     0.00
              0.00  
68970.28 
   9092.51 
   4877.27 
   2702.80 
   1025.14 
    526.97 
    260.34 
     61.08 
      5.54 
      0.00 
0 1000 2000 3000 4000 5000
Acute MI
Pneumonia
Shock
COPD
CHF
Diabetes
Dialysis
IBD
Stroke
Depression
Leukemia
RF
Schizophrenia
Younger Disabled
Aged
Figure 1: The Average PMPM Costs in Various Disease Groups for Two 
Subpopulations  
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Figure 2: Distribution of SFY 2002-03 PMPM Medical Costs in Percentiles among Two 
Subpopulations  
Note: RF is renal failure. IBD is inflammatory bowel disease. CHF is chronic heart 
failure. COPD is chronic obstructive pulmonary disease. MI is myocardial infarction.                        
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Chapter Four 
Discussion 
Capitation payment systems based on risk adjustment methodologies can 
more equitably reimburse health plans with a large proportion of sicker beneficiaries 
if an effective risk adjustment model with high predictive power is developed. In 
former studies exploring risk adjustment methodologies, diagnoses and prescription 
drug usage respectively were used to build predictive models. In this dissertation, a 
model using information about diagnoses and prescription drug usage was built and 
compared with diagnosis-based and pharmacy-based models.  
Since Medicaid beneficiaries other than the aged and the young disabled 
account for a large proportion (83.2 percent), it is necessary to compare the models 
for the aged and the young disabled subpopulations with the models based on the 
whole Medicaid population. The results show that the proposed model and the 
pharmacy-based RxRisk model predict the aged beneficiaries PMPM medical costs 
better than they do for the whole Florida Medicaid populations PMPM costs. The 
variance explained for the aged beneficiaries subpopulation using the proposed 
model is slightly greater than that explained by the RxRisk model. The HCC model, 
however, predicts the general Florida Medicaid populations PMPM costs better than it 
does for the aged beneficiaries costs. All models run against the aged subpopulation 
have higher RMSE and are therefore less accurate than the same models run against 
the general Medicaid population. The pharmacy-based RxRisk model had very close 
predictive performance in contrast to the proposed model for the aged subpopulation 
and it can be a good replacement for the HCC model because of its excellence in 
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predictive performance and practical implementation.  
The proposed model has better or equal predictive ratios than the HCC model 
currently applied in Medicare capitation payment system, for those disease groups 
examined in this dissertation. Predictive ratio is an important factor used to evaluate 
risk adjustment model performance. Predicted PMPM costs in the proposed model are 
closer to the observed costs in the aged Medicaid subpopulation than predicted costs 
using the HCC model. The proposed model also has better performance and accuracy 
than the HCC model for Florida Medicaid capitation payment system. 
The same disease can be associated with differential increases in PMPM costs 
in the aged and the young disabled subpopulations. The disease groups falling within 
different levels of increased costs in both subpopulations are listed in Table 8. The 
increases of PMPM costs for different diseases in the aged and the young disabled 
subpopulations are divided into five levels: less than $0, $0 to $400, $400 to $700, 
$700 to $1,000, more than $1,000. Some HCC categories had negative cost 
increments and these appear in the category <0. 
Within the more than $1,000 increase category, two diseases can be found 
for the aged subpopulation and eight diseases for the young disabled subpopulation. 
For the aged subpopulation, two neurological diseases fell in the category with the 
highest PMPM cost increase: cerebral palsy and multiple sclerosis. Cerebral palsy is 
also associated with the second highest PMPM cost increase in the young disabled 
subpopulation. There is a large gap between younger and older patients medical 
costs for multiple sclerosis. Multiple sclerosis increases the PMPM cost by more than 
$1,000 for the older patients, but falls within the $0-$400 increase in the young 
disabled adults. Multiple sclerosis is costly because it has a major lifetime impact 
(Whetten-Goldstein et al., 1998). The costs for personal assistant and prescription 
drugs are major expenses for multiple sclerosis (Henriksson et al., 2001) and older 
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patients may incur more medical expenditures since they have increased disability 
and more frequent relapse.  
Several diseases fell within the more than $1,000 increase level for the 
young disabled subpopulation. Of these diseases, several can be found in the $700-
$1000 increase level for the aged subpopulation: quadriplegia, head injury, and 
respirator dependence. It is likely that medical care for muscle weakness would be 
associated with high medical costs in both subpopulations since all five diseases 
mentioned above can lead to respiratory weakness and weakness in other body 
systems. Muscular dystrophies consist of genetic disorders characterized by progressive 
muscle wasting and weakness and fell within the more than $1,000 increase level for 
the young disabled subpopulation and the $0-$400 increase level for the aged 
subpopulation. A possible explanation for this finding is that muscular dystrophies can 
be very severe and affect the respiratory system if they begin in childhood. Older 
patients with muscular dystrophies have been found to have less severe symptoms 
and need less medical attention than their younger counterparts. Three medical 
conditions are associated with more than $1,000 increase in PMPM medical cost for 
the young disabled subpopulation but less than $700 for the aged subpopulation: 
artificial openings for feeding or elimination, severe hematological disorders, and 
dialysis status. Patients with these conditions usually need continuous transfusion of 
blood or feeding devices, which can be costly. The results indicate that younger 
disabled Medicaid enrollees need more medical care in transfusion and feeding. 
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Table 8: Disease Groups in Different PMPM Cost Increase Categories for the Aged 
and the Young Disabled Subpopulation 
PMPM Cost Increase 
Categories 
Aged  Younger Disabled 
>1,000 Cerebral Palsy   
Multiple Sclerosis 
Quadriplegia                    
Cerebral Palsy                 
Muscular Dystrophy         
Respirator Dependence    
Artificial Openings for 
Feeding or Elimination      
Severe Hematological 
Disorders                       
Dialysis Status                 
Severe Head Injury         
700-1000 Quadriplegia                    
Schizophrenia                  
Respirator Dependence    
Major Head Injury            
Diabetes with Renal or 
Peripheral Circulatory 
Manifestation               
Protein-Calorie 
Malnutrition           
Metastatic Cancer and 
Acute Leukemia               
HIV/AIDS                        
Opportunistic Infections    
Paraplegia                       
End-Stage Liver Disease   
Protein-Calorie 
Malnutrition                     
Aspiration and Specified 
Bacterial Pneumonias       
Decubitus Ulcer of Skin  
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400-700 Aspiration and Specified 
Bacterial Pneumonias       
HIV/AIDS                        
Parkinsons and 
Huntingtons Diseases      
Paraplegia                       
Seizure Disorders             
Ischemic Stroke               
Decubitus Ulcer of Skin    
Vascular Disease              
Artificial Openings for 
Feeding or Elimination      
Dialysis Status                 
Hemiplegia                      
Coma                    
Amputation Status 
Drug/Alcohol Psychosis     
Amputation Status 
 
Seizure Disorders and 
Convulsions                     
Hemiplegia                      
Septicemia/Shock            
Chronic Ulcer of Skin        
Coma                              
Disorders of Immunity      
Lung, Upper Digestive 
Tract, and Other Severe 
Cancers                     
Renal Failure                   
Vascular Disease with 
Complications                  
Respiratory Arrest            
Intestinal 
Obstruction/Perforation    
Diabetes with Renal or 
Peripheral Circulatory 
Manifestation               
Schizophrenia                  
Parkinsons and 
Huntingtons Diseases    
 
 
 
 
   
 54
0-400 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Major Depressive, 
Bipolar, and Paranoid 
Disorders                        
Intestinal Obstruction       
Renal Failure                   
Chronic Ulcer of Skin        
Septicemia/Shock            
Major Organ Transplant 
Status                             
Vascular Disease with 
Complications                  
Hip Fracture                    
Metastatic Cancer and 
Acute Leukemia               
Major Complications of 
Medical Care and 
Trauma                           
Diabetes with 
Ophthalmologic or 
Unspecified 
Manifestation                 
Diabetes with Neurologic 
or Other Specified 
Manifestation                 
Disorders of Immunity      
Congestive Heart Failure  
Severe Hematological 
Disorders                        
Spinal Cord 
Disorders/Injuries            
Vertebral Fractures 
without Spinal Cord 
Injury                           
Cirrhosis of Liver              
Congestive Heart Failure  
Spinal Cord 
Disorders/Injuries            
Diabetes with Acute 
Complications                 
Diabetes with Neurologic 
or Other Specified 
Manifestation                 
Multiple Sclerosis             
Cardio-Respiratory 
Failure and Shock            
Ischemic Stroke               
Vertebral Fractures 
without Spinal Cord 
Injury                           
Pneumococcal 
Pneumonia               
Hip Fracture/Dislocation   
Major Complications of 
Medical Care and 
Trauma                           
Vascular Disease              
Diabetes with 
Ophthalmologic or 
Unspecified 
Manifestation                 
Chronic Obstructive 
Pulmonary Disease          
Chronic Hepatitis             
Cystic Fibrosis                 
Acute Myocardial 
Infarction                        
Bone/Joint/Muscle 
Infections/Necrosis          
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0-400 Cardio-Respiratory 
Failure and Shock            
Diabetes with Acute 
Complications                  
Traumatic Amputation      
Specified Heart 
Arrhythmias                    
Inflammatory Bowel 
Disease                           
Pancreatic Disease           
 
Bone/Joint/Muscle 
Infections/Necrosis          
Respiratory Arrest            
Cerebral Hemorrhage      
Muscular Dystrophy         
Nephritis                         
End-Stage Liver Disease   
                                     
Specified Heart 
Arrhythmias                    
Pancreatic Disease           
Polyneuropathy               
Diabetes without 
Complication                   
Nephritis                         
Traumatic Amputation      
Drug/Alcohol 
Dependence                    
Major Head Injury   
Unstable Angina and 
Other Acute Ischemic 
Heart Disease                  
Lymphatic, Head and 
Neck, Brain, and Other 
Major Cancers                 
Rheumatoid Arthritis 
and Inflammatory 
Connective Tissue 
Disease 
Breast, Prostate, 
Colorectal and Other 
Cancers and Tumors        
Cirrhosis of Liver              
Major Organ Transplant 
Status       
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<0 Drug or Alcohol 
Dependence                    
Proliferative Diabetic 
Retinopathy and 
Vitreous Hemorrhage       
Rheumatoid Arthritis 
and Inflammatory 
Connective Tissue 
Disease 
Breast, Prostate, 
Colorectal and Other 
Cancers and Tumors        
Acute Myocardial 
Infarction                        
Pneumococcal 
Pneumonia              
Unstable Angina and 
Other Acute Ischemic 
Heart Disease                  
Lung, Upper Digestive 
Tract, and Other Severe 
Cancers           
Lymphatic, Head and 
Neck, Brain, and Other 
Major Cancers                 
Chronic Hepatitis             
Angina Pectoris/Old 
Myocardial Infarction        
Polyneuropathy               
Opportunistic Infections    
Chronic Obstructive 
Pulmonary Disease          
Cystic Fibrosis  
Drug/Alcohol Psychosis     
Cerebral Hemorrhage       
Proliferative Diabetic 
Retinopathy and 
Vitreous Hemorrhage       
Angina Pectoris/Old 
Myocardial Infarction        
Major Depressive, 
Bipolar, and Paranoid 
Disorders                        
Inflammatory Bowel 
Disease                           
Extensive Third-Degree 
Burns         
Note: Diseases in each PMPM cost categories are ranked by amount of costs. 
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 Diseases in the $700-$1000 increase level are mostly of an infectious 
nature for the young disabled subpopulation. Four diseases in this level are directly 
related to opportunistic infections: HIV/AIDS, opportunistic infections, pneumonias, 
and decubitus ulcer of skin. Some diseases in this category have indirect association 
with infections. For example, patients with acute leukemia may have low numbers of 
white cells and their risk for opportunistic infections increases dramatically. End-
stage liver disease and protein-calorie malnutrition lead to low protein levels and a 
decline in the blood antibody level coincident with a fall in the body protein level. 
Opportunistic infections do not increase the medical cost, as predicted by the 
proposed model. The results indicate that medical care for infections cost less in 
older ages.  
 For the aged subpopulation, most diseases in the $700-1000 increase 
category are neurological disorders. Schizophrenia, which is a type of mental 
disorder, is also associated with high medical costs. In the young disabled 
subpopulation, it falls within the $400-$700 categories.  
 Most diseases are associated with higher predicted PMPM medical costs in the 
young disabled subpopulation than in the aged subpopulation. This finding may be 
due to the fact that younger patients suffer more severe medical conditions than 
older patients who have the same diseases. For example, younger patients need 
higher doses of prescription drugs than older patients because they more rapidly 
metabolize medications. Moreover, Medicaid pays for almost all medical costs for 
younger disabled adults, but it only reimburses the costs of prescription drugs for the 
aged subpopulation since older Medicaid beneficiaries are likely to be eligible for 
Medicare and Medicare reimburses many health care services. Hence, PMPM costs of 
the older Medicaid beneficiaries are likely to be underpredicted since Medicaid claims 
do not include all medical expenditures.  
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 Diseases associated with high PMPM costs merit further attention from health 
care providers and investigators. These diseases place a heavy financial burden on 
the Medicaid capitation payment system. Health care providers who find cost-saving 
methods to manage patients with these diseases will reap significant financial 
returns.  
 The proposed model represents an improvement of 15% in variance 
accounted for over the current HCC model for the Medicaid capitation system for the 
aged subpopulation, since the proposed model R2 was 0.32 while the HCC model was 
0.17. However, several changes can be made which may yield further improvements 
in the proposed model. The proposed model has a larger RMSE value for the aged 
and the young disabled subpopulations than the general Medicaid population, which 
may indicate that additional predictors associated with medical costs can be added 
into the proposed model to improve performance. Some pharmacy-based adjusters 
were not included in the proposed model because of potential interactions among the 
current set of predictors, however a possible solution is the statistical transformation 
of these adjusters. Moreover, current RxRisk adjusters were developed for chronic 
conditions only; new RxRisk adjusters for acute conditions should be developed to 
increase the predictive accuracy of models with pharmacy-based adjusters. The 
procedure codes reported in Medicaid claims may contribute unique variance to the 
proposed model and significantly affect the prediction of medical costs. 
 In this dissertation, R-square value and RMSE were used to evaluate the 
predictive power of risk adjustment models, and they are both statistical indicators 
of the overall predictive performance of risk adjustment models. For example, a risk 
adjustment model with high R-square value and low RMSE can predict more variance 
of medical expenditures in the next year than models having lower R-square values 
and higher RMSE. The predictive ratio was used to estimate the power of models 
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using individual risk adjusters and the proposed model had a better predictive ratio 
than the HCC model for the aged subpopulation. However, both models had weak 
predictive performance for some risk adjusters including end-stage liver disease and 
metastatic cancer. In future research some improvements can be made to the 
proposed model. There were two types of health status predictors in the proposed 
model: diagnosis-based HCC adjusters and pharmacy-based RxRisk adjusters. Each 
HCC adjuster represented a group of diseases associated with similar clinical 
characteristics and costs. The distribution of each HCC disease group should be 
examined to find extremely high or low values (outliers). The results show that the 
proposed model poorly predict the costs of some disease groups, such as end-stage 
liver disease and metastatic cancer and a large number of outliers may play a role in 
poor predictive performance of the proposed model for end-stage liver diseases and 
metastatic cancers (Edwards et al., 2000). For example, patients with extremely high 
medical costs within a disease group can make the average cost of this disease 
group increase sharply and risk adjustment models will probably overpredict medical 
costs for other patients in this group. Two possible solutions are the removal of these 
extreme values and the addition of new variables as substitutes for these extreme 
values. The removal of extreme values can decrease variance within a disease group. 
The addition of new variables can divide medical costs for a disease group into two 
groups: extreme values and non-extreme values so researchers can estimate 
average medical costs for both groups, add them into risk adjustment models 
respectively, and address the need of patients with both extreme and non-extreme 
values. Predictive ratio is an important indicator for evaluation of predictive 
performance of models for individual risk adjusters, and both solutions mentioned in 
the early context should be attempted to make the predictive ratio as close to 1 as is 
possible. 
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 Second, adding more variables improves the predictive performance of risk 
adjustment models. Risk adjusters based on durable medical equipment (DME), may 
be a new class of health condition variables. The definition of DME varies across state 
Medicaid systems which have set different standards for DME (www.nls.org). 
Generally, equipment must meet four criteria to be considered DME: (1) it can be 
used repeatedly over extended intervals; (2) it is serves a medical purpose; (3) it is 
functionally useless to persons not having the illness or injury which it was designed 
to ameliorate; (4) it is appropriate for usage at home. These four criteria are the 
only criteria for DME in Florida but different criteria are found for other states. For 
example, the Georgia Medicaid system requires that DME also must have a warranty. 
The Connecticut Medicaid system requires that DME also must be non-disposable. 
The criteria for DME can be found in state Medicaid manuals in different states. DME 
can provide more information on patients health conditions that may be not 
accounted for by diagnosis or pharmaceutical adjusters. For example, wheelchair is a 
DME in Florida. Patients who are in need of wheelchairs may have worse health 
condition than patients without walking difficulties. Hence, patients using wheelchairs 
may incur higher medical costs than their counterparts without walking difficulties. 
However, all these patients are assumed to have same medical costs under risk 
adjustment models without wheelchair variables. In future research using this model, 
all DME will be reviewed and DME that have effects on future medical costs will be 
added into the proposed model to attempt to increase predictive power. 
  Future research will concentrate on improving risk adjustment models and the 
application of improved risk adjustment models in the Florida Medicaid capitation 
payment system. Improvement of risk adjustment models involves empirical reviews 
of statistical methods and clinical practice. An ideal risk adjustment model must have 
strong predictive power and easy implementation in clinical practice. As mentioned 
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earlier, the addition of new variables and removal of outliers may increase predictive 
accuracy of the proposed model. However, the proposed models practical 
implementation must be addressed. The collection of diagnosis-based and pharmacy-
based data may be time-consuming for health plans since both diagnoses and 
prescription drug records must be obtained and used to calculate predicted medical 
costs. Capitation systems based on the proposed model may meet resistance from 
health plans because of the increased workload imposed by this method. Possible 
solutions include the simplification of data-reporting processes for health plans and 
innovations in computer software that can handle more complicated medical costs 
calculations. Capitation payment systems based on the proposed model will have 
several advantages: (1) the proposed model can predict medical costs more 
accurately. The proposed model has more risk adjusters than the HCC model and the 
RxRisk model, and the results in this dissertation have shown that it had more 
predictive power statistically than the competing models. Predicted medical costs 
based on the proposed model will be closer to actual medical costs than medical 
costs predicted by other models; (2) the proposed model can decrease the possibility 
of gaming since it utilizes both diagnostic and pharmaceutical information to predict 
future medical costs. Prescription drug usage can provide more information on 
patients health conditions that cannot be inferred from diagnoses. Hence, patients 
health condition will be more easily identified using the proposed model compared 
with the HCC model. Health plans will have fewer opportunities to game the 
capitation payment system. 
 The RxRisk model is approximately equal to the proposed model in predictive 
accuracy for the aged Medicaid subpopulation. It has advantages in practical 
implementation, such as less work of collecting data and high reliability of data. 
However, it is suggested as a strategy for the aged enrollees only since the 
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predictive accuracy of the RxRisk model for the young disabled subpopulation was 
significantly lower than the proposed model in this study. 
 The proposed model is recommended to be the risk adjustment model for the 
Florida Medicaid capitation payment system because it has been shown to 
outperform competing alternatives. Generally, the proposed model outperformed 
current risk adjustment models in capitation payment systems. As national health 
expenditures keep rising in the near future, improvement of capitation payment 
systems based on risk adjustment methodology is necessary, and this dissertation 
proposes a better model than current ones. It can be implemented in the Florida 
Medicaid capitation payment system to improve predictive accuracy and save 
medical expenditures.  
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